Document:

Prepared by R.R. Donnelley Financial -- EX-10.17

 Exhibit 10.17 

***Confidential Treatment Requested. Confidential portions of this document have been redacted and have been 

separately filed with the Securities and Exchange Commission. 

S09-367 : GWK 
  

 
 AMENDED AND RESTATED EXCLUSIVE AGREEMENT 

This Amended and Restated Agreement (“Restated Agreement”) between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
(“Stanford”), an institution of higher education having powers under the laws of the State of California, and ImmuMetrix, Inc. (“ImmuMetrix”), a corporation having a principal place of business at 3183 Porter Drive, Palo Alto,
CA, is effective on the 27th day of January, 2014, (“Restatement Effective Date”). 
  

	1	BACKGROUND 

 Stanford has an assignment of an invention for a rapid, inexpensive, non-invasive method to
monitor organ transplant recipients for life-threatening graft rejection. It is entitled “Non-invasive diagnosis of graft rejection in organ transplant patients,” was invented in the laboratory of Dr. Stephen Quake, a Howard Hughes
Medical Institute (“HHMI”) investigator at Stanford, and is described in Stanford Docket S09-367. The invention was made in the course of research supported by the National Institutes of Health and HHMI. Stanford wants to have the
invention perfected and marketed as soon as possible so that resulting products may be available for public use and benefit. 
 Effective as of
August 19, 2011 (“Original Sequencing Effective Date”), Stanford and ImmuMetrix, LLC entered into the Exclusive License Agreement (“Sequencing Agreement”) pursuant to which ImmuMetrix, LLC obtained from Stanford a world-wide
exclusive license under the Licensed Patents for use in research and diagnostic fields using sequencing, as more completely set forth in the Sequencing Agreement. Additionally, effective as of February 10, 2012 (“Original PCR Effective
Date”), Stanford and ImmuMetrix, LLC entered into the Exclusive License Agreement (“PCR Agreement”) pursuant to which ImmuMetrix, LLC obtained from Stanford a world-wide exclusive license under the Licensed Patents for use in research
and diagnostic fields using PCR assays, as more completely set forth in the PCR Agreement. 
 As described, and consented to by Stanford, in that certain
letter from ImmuMetrix, LLC to Stanford dated March 26, 2013, ImmuMetrix, LLC assigned to ImmuMetrix, Inc. all rights and obligations under the Sequencing Agreement and the PCR Agreement. 

Now, the parties desire to amend the terms of the Sequencing Agreement and the PCR Agreement and restate the Sequencing Agreement and PCR Agreement in their
entirety on the terms and conditions as set forth in this Restated Agreement. 
  

	2	DEFINITIONS 

  

	2.1	“Agreement” means collectively, (i) the Sequencing Agreement as in effect from the Original Sequencing Agreement Effective Date until the Restatement Effective Date, (ii) the PCR Agreement as in
effect from the Original PCR Effective Date until the Restatement Effective Date and (iii) this Restated Agreement, which pursuant to Section 20.6 below, replaces the Sequencing Agreement and the PCR Agreement in their entirety as of the
Restatement Effective Date. 

  
  

Page 1 of 32 

 S09-367 : GWK 

 
  

	2.2	“Fully Diluted Basis” means the total number of shares of lmmuMetrix’s issued and outstanding common stock, assuming: 

 

	 	(A)	the conversion of all issued and outstanding securities convertible into common stock; 

  

	 	(B)	the exercise of all issued and outstanding warrants or options, regardless of whether then exercisable; and 

  

	 	(C)	the issuance, grant, and exercise of all securities reserved for issuance pursuant to any ImmuMetrix stock or stock option plan then in effect. 

 

	2.3	“HHMI Indemnitees” means HHMI and its trustees, officers, employees, and agents. 

  

	2.4	“Licensed Field of Use” means any and all fields of use. 

  

	2.5	“Licensed Patent” means any domestic or foreign patent application or patent that claims priority to, or common priority with, any application listed in Appendix C. Any claim of an unexpired Licensed Patent is
presumed to be valid unless it has been held to be invalid by a final judgment of a court of competent jurisdiction from which no appeal can be or is taken. “Licensed Patent” excludes any continuation-in-part (CIP) patent application or
patent, provided however that neither party shall file any such patent applications that claim priority to any patent applications that are licensed under this Agreement without the prior written consent of the other party. 

 

	2.6	“Licensed Product” means a product or part of a product in the Licensed Field of Use the making, using, importing or selling of which, absent this license, infringes, induces infringement, or contributes to
infringement of a Valid Claim of a Licensed Patent. For clarity, discovery or development of a product using Licensed Patents or technology or rights licensed hereunder does not cause such product to be a Licensed Product. 

 

	2.7	“Licensed Territory” means worldwide. 

  

	2.8	“Net Sales” means all gross revenue derived through ImmuMetrix or sublicensees from sales of Licensed Product. Net Sales excludes the following items (but only as they pertain to the making, using, importing
or selling of Licensed Products, are included in gross revenue, and are separately billed): 

  

	 	(A)	import, export, excise and sales taxes, and custom duties; 

  

	 	(B)	costs of insurance, packing, and transportation from the place of manufacture to the customer’s premises or point of installation; 

 

	 	(C)	costs of installation at the place of use; and credit for returns, allowances, or trades. 

  

	2.9	 “Nonroyalty Sublicensing Consideration” means any consideration received by ImmuMetrix from a sublicensee as consideration for and allocable
to the grant of a Sublicense under rights 

  
  

Page 2 of 32 

 S09-367 : GWK 

 
  

	 	
under the Licensed Patents in the Licensed Field of Use such as up front fees, annual fees, and milestone fees, without limitation, but excluding any consideration for an earned royalty that is
calculated based on sales of Licensed Product, investments in ImmuMetrix stock or debt, payment or reimbursement of R&D expenses calculated on a fully burdened basis, supply of Licensed Products or other products or materials to such
sublicensee, reimbursement for patent prosecution costs and patent maintenance expenses, licensing of patents or other intellectual property other than Licensed Patents, and the sale of all or substantially all of the business or assets of
ImmuMetrix (or its assignee) whether by merger, sale of stock or assets or otherwise. 

  

	2.10	“Stanford Indemnitees” means Stanford and Stanford Hospitals and Clinics, and their respective trustees, officers, employees, students, and agents. 

 

	2.11	“Sublicense” means any agreement between ImmuMetrix and a third party that contains a grant to Stanford’s Licensed Patents regardless of the name given to the agreement by the parties; however, an
agreement to make, have made, use or sell Licensed Products on behalf of ImmuMetrix is not considered a Sublicense. 

  

	2.12	“Technology” means the Licensed Patents and that additional information or materials listed in Appendix D that will be provided by Stanford to ImmuMetrix. Technology may or may not be confidential in nature.

  

	2.13	“Valid Claim” means a claim contained in an issued and unexpired patent or a pending patent application which has not been held unenforceable or invalid by a decision of a court or other governmental agency of
competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been admitted to be invalid or unenforceable through abandonment, reissue, disclaimer or otherwise. Notwithstanding the foregoing, if a claim of
a pending patent application within the Licensed Patents has not issued as a claim of an issued patent within the Licensed Patents, within five (5) years after the filing date from which such claim takes priority, such pending claim shall not
be a Valid Claim for purposes of this Agreement. 

  

	3	GRANT 

  

	3.1	Grant. Subject to the terms and conditions of this Agreement, Stanford grants ImmuMetrix (a) an exclusive license under the Licensed Patent in the Licensed Field of Use to make, have made, use, import, offer
to sell and sell Licensed Product in the Licensed Territory and (b) a non-exclusive license under the Technology in the Licensed Field of Use to research, develop, make, have made, use, import, offer to sell and sell Licensed Product and
otherwise exploit Technology in the Licensed Territory. 

  

	3.2	Term. The license terminates when the last of the Licensed Patents expires, provided that ImmuMetrix’s non-exclusive license under the Technology set forth in Section 3.1(b) shall survive such
expiration with respect to Technology in ImmuMetrix’s possession. 

  
  

Page 3 of 32 

 S09-367 : GWK 

 
  

	3.3	Retained Rights. Stanford retains the right, on behalf of itself and all other non-profit academic research institutions, to practice the Licensed Patent and use Technology for any non-profit purpose, including
sponsored research and collaborations. ImmuMetrix agrees that, notwithstanding any other provision of this Agreement, it has no right to enforce the Licensed Patent against any such institution. Stanford and any such other institution have the right
to publish any information included in the Technology or a Licensed Patent. ImmuMetrix acknowledges that HHMI has retained an irrevocable, perpetual, worldwide, royalty-free, nonexclusive, nontransferable license to the Licensed Patents and
Technology. 

  

	3.4	Specific Exclusion. Stanford does not: 

  

	 	(A)	grant to ImmuMetrix any other licenses, implied or otherwise, to any patents or other rights of Stanford other than those rights granted under Licensed Patent, regardless of whether the patents or other rights are
dominant or subordinate to any Licensed Patent, or are required to exploit any Licensed Patent or Technology; 

  

	 	(B)	commit to ImmuMetrix to bring suit against third parties for infringement, except as described in Article 14; and 

  

	 	(C)	agree to furnish to ImmuMetrix any technology or technological information other than the Technology or to provide ImmuMetrix with any assistance. 

 

	4	SUBLICENSING 

  

	4.1	Permitted Sublicensing. ImmuMetrix may grant and authorize sublicenses in the Licensed Field of Use only if at the time of such grant ImmuMetrix or its sublicensee is developing or selling Licensed Products.
Sublicenses with any exclusivity must include diligence requirements commensurate with the diligence requirements of Appendix A. Stanford agrees that ImmuMetrix may apportion a commercially reasonable percentage of sublicensing payments made to
Stanford pursuant to Section 4.6, provided however that ImmuMetrix provides Stanford with the proposed apportionment and justification prior ImmuMetrix’s payment pursuant to Section 8.1. Stanford and ImmuMetrix agree to meet to
discuss such proposed apportionment if in Stanford’s opinion the apportionment does not reasonably reflect the value of the Licensed Patents. 

  

	4.2	Required Sublicensing. If ImmuMetrix is unable or unwilling to serve or develop a potential market or market territory for which there is a company willing to be a sublicensee, ImmuMetrix will, at Stanford’s
request, negotiate in good faith a Sublicense with any such sublicensee. Stanford would like licensees to address unmet needs, such as those of neglected patient populations or geographic areas, giving particular attention to improved therapeutics,
diagnostics and agricultural technologies for the developing world. 

  

	4.3	Sublicense Requirements. Any Sublicense granted under this Agreement: 

  

	 	(A)	is subject to this Agreement; 

  

	 	(B)	will prohibit sublicensee from paying royalties to an escrow or other similar account; 

  
  

Page 4 of 32 

 S09-367 : GWK 

 
  

	 	(C)	will expressly include the provisions of Articles 8, 9, 10, 12, and Section 19.4 for the benefit of Stanford and/or HHMI, as the case may be; and 

 

	 	(D)	will require the transfer of all the sublicensee’s applicable obligations to ImmuMetrix with respect to the sublicense, including the payment of royalties specified in the Sublicense (up to the earned royalty rates
set forth in Article 7)), to Stanford or its designee, if this Agreement is terminated. If the sublicensee is a spin-out from ImmuMetrix, ImmuMetrix must guarantee the sublicensee’s performance with respect to the payment of Stanford’s
share of Sublicense royalties. 

  

	4.4	Copy of Sublicenses and Sublicensee Royalty Reports. ImmuMetrix will submit to Stanford a copy of each Sublicense, any subsequent amendments and all copies of sublicensees’ royalty reports. Beginning with the first
Sublicense, the Chief Financial Officer or equivalent will certify annually regarding the name and number of sublicensees. 

  

	4.5	Litigation by Sublicensee. Any Sublicense must include the following clauses: 

  

	 	(A)	In the event sublicensee brings an action seeking to invalidate any Licensed Patent: 

  

	 	(1)	sublicensee will double the payment paid to the ImmuMetrix during the pendency of such action. Moreover, should the outcome of such action determine that any claim of a patent challenged by the sublicensee is both valid
and infringed by a Licensed Product, sublicensee will pay triple times the payment paid under the original Sublicense; 

  

	 	(2)	sublicensee will have no right to recoup any royalties paid before or during the period challenge; 

  

	 	(3)	any dispute regarding the validity of any Licensed Patent shall be litigated in the courts located in Santa Clara County, and the parties agree not to challenge personal jurisdiction in that forum; 

 

	 	(4)	sublicensee shall not pay royalties into any escrow or other similar account. 

  

	 	(B)	Sublicensee will provide written notice to Stanford at least three months prior to bringing an action seeking to invalidate a Licensed Patent. Sublicensee will include with such written notice an identification of all
prior art it believes invalidates any claim of the Licensed Patent. 

 Notwithstanding the foregoing, in the event a
sublicensee files a counterclaim asserting invalidity of one or more Licensed Patents in response to an actual suit by Stanford, such sublicensee shall not be deemed to have brought an action to invalidate a Licensed Patent and this Section 4.5
shall not apply. 

  
  

Page 5 of 32 

 ***Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
 S09-367 : GWK 
  

 

	4.6	Sharing of Sublicensing Income. ImmuMetrix will pay Stanford the following percent of all Nonroyalty Sublicensing Consideration, excluding earned royalties (ImmuMetrix shall guarantee earned royalties for sales
by sublicensees as if the sales were made by ImmuMetrix): 

  

	 	(A)	[***]% of Nonroyalty Sublicensing Consideration before and [***]% of Nonroyalty Consideration after demonstration, that cell free DNA of a transplanted organ, other than a human heart, may be detected in the blood or
other bodily fluids or tissues of the host, and that the cell free DNA concentration increases during a transplant rejection event as identified by other established clinical means, but before occurrence of an event listed in clause (B) below;

  

	 	(B)	[***]% of Nonroyalty Sublicensing Consideration after the earlier of (i) commercial launch as indicated by a first sale or (ii) expenditure after the Restatement Effective date of $[***] for the research,
development, regulatory approval and/or commercialization, in either case of a Licensed Product by ImmuMetrix directly or through its Affiliates, sublicensees and/or other contractors, but before occurrence of the event listed in clause
(C) below; or 

  

	 	(C)	[***]% of Nonroyalty Sublicensing Consideration after annual sales of Licensed Product by ImmuMetrix, its Affiliates and/or its sublicensees reach $[***]. 

 

	4.7	Royalty-Free Sublicenses. If ImmuMetrix pays all royalties due Stanford from a sublicensee’s Net Sales, ImmuMetrix may grant that sublicensee a royalty-free or non-cash: 

 

	 	(A)	Sublicense or 

  

	 	(B)	cross-license. 

  

	5	GOVERNMENT RIGHTS 

 This Agreement is subject to Title 35 Sections 200-204 of the United States Code.
Among other things, these provisions provide the United States Government with nonexclusive rights in the Licensed Patent. They also impose the obligation that Licensed Product sold or produced in the United States be “manufactured
substantially in the United States.” ImmuMetrix will ensure all obligations of these provisions are met. 
  

	6	DILIGENCE 

  

	6.1	 Milestones. Because the invention is not yet commercially viable as of the Original Sequencing Effective Date, ImmuMetrix, directly or through its
Affiliates, sublicensees and/or other contractors, will diligently develop, manufacture, and sell and/or otherwise commercialize Licensed Product and will diligently develop markets for Licensed Product. In addition, ImmuMetrix, directly or through
its Affiliates, sublicensees and/or other contractors, will meet the milestones shown in Appendix A, and notify Stanford in writing as each milestone is met. Notwithstanding the foregoing and 15.2(A)(3), Stanford shall not unreasonably withhold its
consent to any revision of the milestones described in Appendix A when requested in writing by ImmuMetrix to the extent such request is supported by evidence of technical difficulties or delays, including in clinical studies or regulatory

  
  

Page 6 of 32 

 ***Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
 S09-367 : GWK 
  

 

	 	
processes, outside of ImmuMetrix’s reasonable control. Additionally, ImmuMetrix shall be entitled to extend the due date of any one and any subsequent milestones described on Appendix A by
[***] year upon payment to Stanford of [***] Dollars ($[***]) (a “[***]-Year Extension”), but only once for each milestone. ImmuMetrix shall have the right to extend such due dates from time to time for additional [***]-Year Extensions in
accordance with the foregoing, but only after discussion and agreement by Stanford, such agreement not to be unreasonably withheld. Any such extension of a milestone due date shall also extend the due date for all subsequent related milestones by
[***] year. 

  

	6.2	Progress Report. By March 1 of each year, ImmuMetrix will submit a written annual report to Stanford covering the preceding calendar year. The report will include information sufficient to enable Stanford to
satisfy reporting requirements of the U.S. Government and for Stanford to ascertain progress by ImmuMetrix toward meeting this Agreement’s diligence requirements. Each report will describe, where relevant: ImmuMetrix’s progress toward
commercialization of Licensed Product, including work completed, key scientific discoveries, summary of work-in-progress, current schedule of anticipated events or milestones, market plans for introduction of Licensed Product, and significant
corporate transactions involving Licensed Product. 

  

	6.3	Clinical Trial Notice. ImmuMetrix will notify Stanford prior to commencing any clinical trials at Stanford. 

  

	6.4	Completed Milestones. Stanford acknowledges and agrees that ImmuMetrix has met the milestones numbered 1 through 6 set forth in Appendix A. 

 

	7	ROYALTIES 

  

	7.1	Issue Royalty. Stanford and ImmuMetrix acknowledge and agree that in consideration of the grant of the license hereunder, ImmuMetrix has paid to Stanford a noncreditable, nonrefundable license issue royalty of
$20,000 upon signing the PCR Agreement and a noncreditable, nonrefundable license issue royalty of $20,000 upon signing the Sequencing Agreement and no addition issue royalty, except as set forth in Section 7.16 hereof, shall be due upon the
signing of this Restated Agreement. 

  

	7.2	License Maintenance Fee. ImmuMetrix will pay Stanford a yearly license maintenance fee as follows: 

  

	 	(A)	$[***] upon the first anniversary of the Restated Agreement; 

  

	 	(B)	$[***] upon the second anniversary of the Restated Agreement; and 

  

	 	(C)	$[***] upon the third and each subsequent anniversary of the Restated Agreement during the term of this Restated Agreement. 

Yearly maintenance payments are nonrefundable, but they are creditable each year as described in Section 7.6. 

  
  

Page 7 of 32 

 ***Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
 S09-367 : GWK 
  

 

	7.3	Milestone Payments. ImmuMetrix will pay Stanford the following milestone payments with respects of the first Licensed Product: 

 

							
			
	(a)	  	Initiation of any clinical trial	  	 	$[***]	  
			
	(b)	  	First commercial sale	  	 	$[***]	  
			
	(c)	  	FDA or ex-US equiv. approval	  	 	$[***]	  
			
	(d)	  	Sales > $[***]	  	 	$[***]	  
			
	(e)	  	Patent Issuance	  	 	$[***]	  
			
	(f)	  	Net Sales of Licensed Product exceeds $[***]	  	 	$[***]	  

  

	7.4	Earned Royalty. ImmuMetrix will pay Stanford earned royalties (Y%) on Net Sales as follows: 

ImmuMetrix or its sublicensee will pay Stanford a [***]% royalty on Net Sales of each Licensed Product sold. 

Earned royalties paid to third parties will offset Stanford earned royalties at a rate [***]% for each [***]% that ImmuMetrix pays to third
parties provided that the third party technology for which ImmuMetrix pays earned royalties is reasonably useful and the earned royalty rate ImmuMetrix pays them is commercially reasonable for the type of technology and such license is reasonably
useful to make, use and sell the Licensed Product, licensed hereunder. In no event shall the royalty be reduced by more than [***]%. 
 In
the event that a Licensed Product is sold in combination with one or more other products or components for which no royalty would be due hereunder if sold separately (“Other Product(s)”), Net Sales from such sales shall be calculated by
multiplying the net selling price of the combination product by the fraction A/(A + B), where A is the average gross selling price during the applicable calendar quarter of the Licensed Product sold separately and B is the average gross selling
price during the applicable calendar quarter of the Other Product(s). In the event that separate sales of the Licensed Product and/or of the Other Product(s) were not made during the applicable calendar quarter, then the Net Sales on the combination
product shall be as reasonably as mutually agreed upon by Stanford and ImmuMetrix in good faith, between such Licensed Product and such Other Product(s), based upon their relative importance and proprietary protection. In the event that Stanford
reasonably believes that the average gross selling price during the applicable calendar quarter of the Licensed Product sold separately and the Other Product(s) sold separately do not accurately reflect the relative importance and proprietary
protection of the Licensed Product and such Other Product(s) for the purposes of determining Net Sales of a combination product, Stanford may provide ImmuMetrix notice thereof and the parties thereafter shall reasonably discuss and agree in good
faith upon an alternative allocation with respect thereto. If the parties cannot so agree, the matter will be resolved by arbitration in accordance with Article 17. 

  
  

Page 8 of 32 

 ***Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
 S09-367 : GWK 
  

 
 For clarity, ImmuMetrix’s right to offset earned royalties for
third party technology as set forth above shall not apply with respect to third party technology reasonably useful to make, use and sell a Licensed Product that is a combination product for which Net Sales is calculated as set forth in the preceding
paragraph to the extent such third party technology is only useful for the making, using or selling the Other Product(s) in such combination product separately. 
  

	7.5	Earned Royalty if ImmuMetrix or Sublicensee Challenges the Patent. Notwithstanding the above, should ImmuMetrix bring an action seeking to invalidate any Licensed Patent, ImmuMetrix will pay royalties to Stanford
at the rate of [***] x Y percent ([***] xY%) of the Net Sales of all Licensed Products sold during the pendency of such action. Moreover, should the outcome of such action determine that any claim of a patent challenged by ImmuMetrix is both
valid and infringed by a Licensed Product, ImmuMetrix will pay royalties at the rate of [***] x Y percent ([***] xY%) of the Net Sales of all Licensed Products sold. Notwithstanding the foregoing, in the event ImmuMetrix files a counterclaim
asserting invalidity of one or more Licensed Patents in response to an actual suit by Stanford, ImmuMetrix shall not be deemed to have brought an action to invalidate a Licensed Patent and this Section 7.5 shall not apply.

  

	7.6	Creditable Payments. The license maintenance fee for a year may be offset against earned royalty payments due on Net Sales occurring in that year. 

For example: 
  

	 	(A)	if ImmuMetrix pays Stanford a $[***] maintenance payment for year Y, and according to Section 7.4 $[***] in earned royalties are due Stanford for Net Sales in year Y, ImmuMetrix will only need to pay Stanford an
additional $[***] for that year’s earned royalties. 

  

	 	(B)	if ImmuMetrix pays Stanford a $[***] maintenance payment for year Y, and according to Section 7.4 $[***] in earned royalties are due Stanford for Net Sales in year Y, ImmuMetrix will not need to pay Stanford any
earned royalty payment for that year. ImmuMetrix will not be able to offset the remaining $[***] against a future year’s earned royalties. 

  

	7.7	Obligation to Pay Royalties. A royalty is due Stanford under this Agreement for any activity conducted under the licenses granted. For convenience’s sake, the amount of that royalty is calculated using Net
Sales. Nonetheless, if certain Licensed Products are made, used, imported, or offered for sale before the date this Agreement terminates, and those Licensed Products are sold after the termination date, ImmuMetrix will pay Stanford an earned royalty
for its exercise of rights based on the Net Sales of those Licensed Products. 

  

	7.8	No Escrow. ImmuMetrix shall not pay royalties into any escrow or other similar account. 

  

	7.9	Currency. ImmuMetrix will calculate the royalty on sales in currencies other than U.S. Dollars using the appropriate foreign exchange rate for the currency quoted by the Wall Street Journal on the close of
business on the last banking day of each calendar quarter. ImmuMetrix will make royalty payments to Stanford in U.S. Dollars. 

  
  

Page 9 of 32 

 ***Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
 S09-367 : GWK 
  

 

	7.10	Non-U. S. Taxes. ImmuMetrix will pay all non-U.S. taxes related to royalty payments. These payments are not deductible from any payments due to Stanford. 

 

	7.11	Interest. Any payments not made when due will bear interest at the lower of (a) the Prime Rate published in the Wall Street Journal plus 200 basis points or (b) the maximum rate permitted by law.

  

	7.12	[***]% Purchase Right. In any private offering of ImmuMetrix’s equity securities for cash (or in satisfaction of debt issued for cash), Stanford may purchase for cash up to [***]% of the securities issued in
such offering. This right will expire following the first round of bona fide equity investment in ImmuMetrix from a single or group of investors which includes at least one venture capital, professional angel, corporate or other similar
institutional investor and which either (i) is at least $[***] in size or (ii) involves the sale to outside investors of at least [***]% of the shares outstanding after such round on a Fully-Diluted Basis, but will apply to all shares to
be issued in such round. 

  

	7.13	Future Offerings. In any private offering of ImmuMetrix’s equity securities in exchange for cash (or in satisfaction of debt issued for cash), Stanford may purchase for cash that number of the securities
issued in such offering as is necessary for Stanford to maintain its pro rata ownership interest in ImmuMetrix on a Fully-Diluted Basis. This right is in addition to Stanford’s rights under Section 7.12. If both Section 7.12 and this
Section 7.13 apply to an offering, the provision granting Stanford the greater purchase rights will govern. 

  

	7.14	 Purchase Terms and Procedure, Exceptions; Public Offering. In any offering subject to Section 7.12 or 7.13,
(i) Stanford’s purchase right shall be on the same terms as the other investors in the financing in question, except that Stanford shall not have any board representation or board meeting attendance rights, (ii) ImmuMetrix will give
Stanford notice of the terms of the offering, including the names of the investors and the amounts to be invested by each, and Stanford may elect to exercise its right of purchase, in whole or in part, by notice given to ImmuMetrix within 20 days
after receipt of ImmuMetrix’s notice and (iii) if Stanford elects not to purchase, or fails to give an election notice within such period, Stanford’s purchase right will not apply to the offering if (and only if and to the extent) it
is consummated within 90 days on the same or less favorable (to the investor) terms as stated in ImmuMetrix’s notice to Stanford. Stanford’s rights under Sections 7.12 and 7.13 will not apply to the issuance of stock: (i) to employees
and other service providers pursuant to a plan approved by ImmuMetrix’s Board of Directors; (ii) as additional consideration in lending or leasing transactions, or (iii) to any person or entity pursuant to an arrangement that the
ImmuMetrix’s Board of Directors determines in good faith is a strategic partnership, licensing transaction or other arrangement which is not primarily for the purpose of raising capital. In the event of the closing of a firm commitment
underwritten public offering, the rights granted in Sections 7.12 and 7.13 will terminate (in addition to any earlier termination pursuant to their terms) immediately before such closing. The rights granted in Section 7.13 will also terminate
upon a bona-fide acquisition of ImmuMetrix by a third party if the  

  
  

Page 10 of 32 

 S09-367 : GWK 

 
  

	 	
acquisition is deemed by ImmuMetrix’s Board of Directors to be in the best interest of its stockholders and the acquisition results in the termination of all such similar rights held by its
stockholders in connection with the acquisition. 

  

	7.15	Repurchase Obligation. If Stanford is to conduct any clinical trial on behalf of ImmuMetrix or any agent of ImmuMetrix, ImmuMetrix will repurchase all Stanford’s equity interest in ImmuMetrix prior to
beginning such trial, if requested by Stanford. The repurchase price for any such equity interest will be the fair market value for that equity at the time ImmuMetrix and Stanford enter into a definitive agreement under which any such clinical
research will be performed. Fair market value of publicly traded equity instruments will be determined by taking the average of the closing price for such equity over the five days preceding such date. Fair market value of non-public equity
instruments will be at least as high as the greater of: 

  

	 	(A)	the last value placed on any such equity in ImmuMetrix through an arms-length transaction regarding the issuance or sale of any equity in ImmuMetrix; or 

 

	 	(B)	the last value placed on any such equity by ImmuMetrix’s Board of Directors in connection with any transaction other than this repurchase of shares from Stanford. 

 

	7.16	Equity Interest. As further consideration for the license granted hereunder and the restatement of the Sequencing Agreement and the PCR Agreement into this Restated Agreement, ImmuMetrix shall, subject to the
approval of ImmuMetrix’s Board of Directors and Stanford’s execution and delivery to ImmuMetrix of ImmuMetrix’s standard form of stock purchase agreement attached hereto as Appendix E, grant to Stanford 700,000 shares of common stock
in ImmuMetrix. When issued, those shares will represent 1.451% of the common stock in ImmuMetrix on a Fully Diluted Basis. ImmuMetrix agrees to provide Stanford with a capitalization table upon which the above calculation is made. ImmuMetrix will,
subject to each inventor’s execution and delivery to ImmuMetrix of ImmuMetrix’s standard form of stock purchase agreement attached hereto as Appendix E, issue 28.34% of all shares granted to Stanford pursuant to this Section 7.16
directly to and in the name of the inventors listed allocated as stated below: 

  

	 	A)	Stephen Quake — 66,127 shares 

  

	 	B)	Thomas Snyder — 66,127 shares 

  

	 	C)	Hannah Valantine- 66,127 shares 

  

	8	ROYALTY REPORTS, PAYMENTS, AND ACCOUNTING 

  

	8.1	 Quarterly Earned Royalty Payment and Report. Beginning with the first sale of a Licensed Product by ImmuMetrix or a sublicensee, ImmuMetrix
will submit to Stanford a written report (even if there are no sales) and an earned royalty payment within 30 days after the end of each calendar quarter. This report will be in the form of Appendix B and will state the number, description, and
aggregate Net Sales of Licensed Product during the completed calendar quarter. The report will include an overview of the process and documents relied  

  
  

Page 11 of 32 

 S09-367 : GWK 

 
  

	 	
upon to permit Stanford to understand how the earned royalties are calculated. With each report ImmuMetrix will include any earned royalty payment due Stanford for the completed calendar quarter
(as calculated under Section 7.4). 

  

	8.2	No Refund. In the event that a validity or non-infringement challenge of a Licensed Patent brought by ImmuMetrix is successful, ImmuMetrix will have no right to recoup any royalties paid before or during the
period challenge. 

  

	8.3	Termination Report. ImmuMetrix will pay to Stanford all applicable royalties and submit to Stanford a written report within 90 days after the license terminates. ImmuMetrix will continue to submit earned royalty
payments and reports to Stanford after the license terminates, until all Licensed Products made or imported under the license have been sold. 

  

	8.4	Accounting. ImmuMetrix will maintain records showing manufacture, importation, sale, and use of a Licensed Product for 7 years from the date of sale of that Licensed Product. Records will include general-ledger
records showing cash receipts and expenses, and records that include: production records, customers, invoices, serial numbers, and related information in sufficient detail to enable Stanford to determine the royalties payable under this
Agreement. 

  

	8.5	Audit by Stanford. ImmuMetrix will allow Stanford or its designee to examine ImmuMetrix’s records to verify payments made by ImmuMetrix under this Agreement. 

 

	8.6	Paying for Audit. Stanford will pay for any audit done under Section 8.5. But if the audit reveals an underreporting of earned royalties due Stanford of 5% or more for the period being audited, ImmuMetrix
will pay the audit costs. 

  

	8.7	Self-audit. ImmuMetrix will conduct an independent audit of sales and royalties at least every 2 years if annual sales of Licensed Product are over $5,000,000. The audit will address, at a minimum, the amount of
gross sales by or on behalf of ImmuMetrix during the audit period, the amount of funds owed to Stanford under this Agreement, and whether the amount owed has been paid to Stanford and is reflected in the records of ImmuMetrix. ImmuMetrix will submit
the auditor’s report promptly to Stanford upon completion. ImmuMetrix will pay for the entire cost of the audit. 

  

	9	EXCLUSIONS AND NEGATION OF WARRANTIES 

  

	9.1	Negation of Warranties. Stanford provides ImmuMetrix the rights granted in this Agreement AS IS and WITH ALL FAULTS. Stanford makes no representations and extends no warranties of any kind, either express or
implied. Among other things, Stanford disclaims any express or implied warranty: 

  

	 	(A)	of merchantability, of fitness for a particular purpose, 

  

	 	(B)	of non-infringement or 

  
  

Page 12 of 32 

 S09-367 : GWK 

 
  

	 	(C)	arising out of any course of dealing. 

  

	9.2	No Representation of Licensed Patent. ImmuMetrix also acknowledges that Stanford does not represent or warrant: 

  

	 	(A)	the validity or scope of any Licensed Patent, or 

  

	 	(B)	that the exploitation of Licensed Patent or Technology will be successful. 

  

	10	INDEMNITY 

  

	10.1	Indemnification. 

  

	 	(A)	ImmuMetrix will indemnify, hold harmless, and defend all Stanford Indemnitees against any claim of any kind arising out of or related to the exercise of any rights granted ImmuMetrix under this Agreement or the breach
of this Agreement by ImmuMetrix. 

  

	 	(B)	HHMI Indemnitees will be indemnified, defended by counsel acceptable to HHMI, and held harmless by ImmuMetrix from and against any claim, liability, cost, expense, damage, deficiency, loss, or obligation, of any kind or
nature (including, without limitation, reasonable attorneys’ fees and other costs and expenses of defense) (collectively, “Claims”), based upon, arising out of, or otherwise relating to this Agreement, including without limitation any
cause of action relating to product liability. The previous sentence will not apply to any Claim that is determined with finality by a court of competent jurisdiction to result solely from the gross negligence or willful misconduct of an HHMI
Indemnitee. 

  

	10.2	No Indirect Liability. Stanford is not liable for any special, consequential, lost profit, expectation, punitive or other indirect damages in connection with any claim arising out of or related to this Agreement,
whether grounded in tort (including negligence), strict liability, contract, or otherwise. 

  

	10.3	Workers’ Compensation. ImmuMetrix will comply with all statutory workers’ compensation and employers’ liability requirements for activities performed under this Agreement. 

 

	10.4	 Insurance. Upon the first use of Licensed Products with human samples, including but not limited to testing or clinical trials but excluding
tests with human tissues obtained from tissue banks or discarded human tissues under an IRB approved study, ImmuMetrix will maintain Comprehensive General Liability Insurance, including Product Liability insurance, with a reputable and financially
secure insurance carrier to cover the activities of ImmuMetrix and its sublicensees. The insurance will provide minimum limits of liability of $2,000,000 and will include all Stanford Indemnitees and HHMI Indemnitees as additional insureds.
Insurance must cover claims incurred, discovered, manifested, or made during or after the expiration of this Agreement and must be placed with carriers with ratings of at least A- as rated by A.M. Best. Within 15 days after Stanford’s request
and after the first use of  

  
  

Page 13 of 32 

 S09-367 : GWK 

 
  

	 	
Licensed Products with human samples as described above, ImmuMetrix will furnish a Certificate of Insurance evidencing primary coverage and additional insured requirements. ImmuMetrix will
provide to Stanford 30 days prior written notice of cancellation or material change to this insurance coverage. ImmuMetrix will advise Stanford in writing that it maintains excess liability coverage (following form) over primary insurance for at
least the minimum limits set forth above. All insurance of ImmuMetrix will be primary coverage; insurance of the Stanford Indemnitees and the HHMI Indemnitees will be excess and noncontributory. 

 

	11	EXPORT 

 ImmuMetrix and its affiliates and sublicensees shall comply with all United States laws and
regulations controlling the export of licensed commodities and technical data. (For the purpose of this paragraph, “licensed commodities” means any article, material or supply but does not include information; and “technical
data” means tangible or intangible technical information that is subject to US export regulations, including blueprints, plans, diagrams, models, formulae, tables, engineering designs and specifications, manuals and instructions.) These laws
and regulations may include, but are not limited to, the Export Administration Regulations (15 CFR 730-774), the International Traffic in Arms Regulations (22 CFR 120-130) and the various economic sanctions regulations administered by the US
Department of the Treasury (31 CFR 500-600). 
 Among other things, these laws and regulations prohibit or require a license for the export or retransfer of
certain commodities and technical data to specified countries, entities and persons. ImmuMetrix hereby gives written assurance that it will comply with, and will cause its affiliates and sublicensees to comply with all United States export control
laws and regulations, that it bears sole responsibility for any violation of such laws and regulations by itself or its affiliates or sublicensees, and that it will indemnify, defend and hold Stanford harmless for the consequences of any such
violation. 
  

	12	MARKING 

 Before any Licensed Patent issues, ImmuMetrix will mark Licensed Product with the words
“Patent Pending.” Otherwise, ImmuMetrix will mark Licensed Product with the number of any issued Licensed Patent. 
  

	13	NAMES AND MARKS 

 IMMUMETRIX WILL NOT IDENTIFY STANFORD OR HHMI IN ANY PROMOTIONAL
STATEMENT, OR OTHERWISE USE THE NAME OF ANY STANFORD OR HHMI FACULTY MEMBER, EMPLOYEE, OR STUDENT, OR ANY TRADEMARK, SERVICE MARK, TRADE NAME, OR SYMBOL OF STANFORD OR STANFORD HOSPITALS AND
CLINICS, OR HHMI, INCLUDING THE STANFORD OR HHMI NAME, UNLESS IMMUMETRIX HAS RECEIVED STANFORD’S OR HHMI’S PRIOR WRITTEN CONSENT, AS THE CASE MAY BE, PERMISSION MAY BE WITHHELD AT STANFORD’S OR
HHMI’S SOLE DISCRETION. 

  
  

Page 14 of 32 

 S09-367 : GWK 

 
  

	14	PROSECUTION AND PROTECTION OF PATENTS 

  

	14.1	Patent Prosecution. Following the Original Sequencing Effective Date, Stanford will be responsible for preparing, filing, and prosecuting broad patent claims (including any interference or reexamination actions)
for Stanford’s benefit in the Licensed Territory and for maintaining all Licensed Patents. Stanford will notify ImmuMetrix before taking any substantive actions in prosecuting the claims, and Stanford will have final approval on how to proceed
with any such actions. 

  

	14.2	Patent Costs. Within 30 days after receiving a statement from Stanford, ImmuMetrix will reimburse Stanford for all Licensed Patent’s patenting expenses, including any interference or reexamination matters,
(“Patent Costs”) incurred by Stanford after the Restatement Effective Date. In all instances, Stanford will pay the fees prescribed for large entities to the United States Patent and Trademark Office. 

 

	14.3	Infringement Procedure. Each party will promptly notify the other if it believes a third party infringes a Licensed Patent or if a third party files a declaratory judgment action relating to the Licensed Patents.
During the term of this Agreement and if ImmuMetrix is developing Licensed Product, ImmuMetrix may have the right to institute a suit against this third party as provided in Sections 14.4 - 14.8. 

 

	14.4	ImmuMetrix Suit. ImmuMetrix, itself or through a designee, has the first right to institute suit, or defend any action for declaratory judgment, relating to the Licensed Patents and may name Stanford, subject to
the requirements of this Section 14.4, as a party for standing purposes. If ImmuMetrix decides to institute suit, it will notify Stanford in writing. ImmuMetrix will bear the entire cost of the litigation. Stanford may be named as a party in a
suit initiated by ImmuMetrix (other than in accordance with Section 14.5) only if: 

  

	 	(A)	ImmuMetrix’s and Stanford’s counsel recommend that such action is necessary in their reasonably opinion to achieve standing or a court has required or will require such joinder to pursue the action.

  

	 	(B)	Stanford is not the first name party in the action; and 

  

	 	(C)	The pleadings and any public statements about the action state that ImmuMetrix is pursuing the action and that ImmuMetrix has the right to join Stanford as a party. 

 

	14.5	Joint Suit. If Stanford and ImmuMetrix so agree, they may institute suit jointly. If so, they will: 

  

	 	(A)	prosecute the suit in both their names; 

  

	 	(B)	bear the out-of-pocket costs equally; 

  

	 	(C)	share any recovery or settlement equally; and 

  

	 	(D)	agree how they will exercise control over the action. 

  
  

Page 15 of 32 

 S09-367 : GWK 

 
  
  

	14.6	Stanford Suit. If ImmuMetrix does not initiate an enforcement action within 120 days of a request by Stanford to do so or ImmuMetrix does not elect to control a declaratory judgment action within 90 days of
receiving notice that such action has been filed, Stanford may institute and prosecute a suit so long as it conforms with the requirements of this Section. Stanford will diligently pursue the suit and will bear the entire cost of the litigation,
including expenses and counsel fees incurred by ImmuMetrix. Stanford will keep ImmuMetrix reasonably apprised of all developments in the suit, and will seek ImmuMetrix’s input and approval on any substantive submissions or positions taken in
the litigation regarding the scope, validity and enforceability of the Licensed Patent. Stanford will not prosecute, settle or otherwise compromise any such suit in a manner that adversely affects ImmuMetrix’s interests without
ImmuMetrix’s prior written consent. 

  

	14.7	Recovery. If ImmuMetrix sues under Section 14.4, then any recovery in excess of any unrecovered litigation costs and fees will be shared with Stanford as follows: 

 

	 	(A)	any payment for past sales will be deemed Net Sales, and ImmuMetrix will pay Stanford royalties at the rates specified in Section 7.4; 

 

	 	(B)	any payment for future sales will be deemed a payment under a Sublicense, and royalties will be shared as specified in Article 4. 

  

	 	(C)	ImmuMetrix and Stanford will negotiate in good faith appropriate compensation to Stanford for any non-cash settlement or non-cash cross-license. 

 

	14.8	Abandonment of Suit. If either Stanford or ImmuMetrix commences a suit and then wants to abandon the suit, it will give timely notice to the other party. The other party may continue prosecution of the suit after
Stanford and ImmuMetrix agree on the sharing of expenses and any recovery in the suit. 

  

	14.9	Cooperation. The non-controlling party shall, at the reasonable request and expense of the party controlling any enforcement or declaratory action under this Article 14, fully cooperate with the controlling
party, including making available relevant records, papers, information, samples, specimens, and the like. The party controlling the enforcement or declaratory action shall keep the non-controlling party reasonably informed of the progress of such
action, and the non-controlling party shall have the right to participate in such enforcement or declaratory action with counsel of its own choice at its own expense. 

 

	15	TERMINATION 

  

	15.1	Termination by ImmuMetrix. ImmuMetrix may terminate this Agreement by giving Stanford written notice at least 30 days in advance of the effective date of termination selected by ImmuMetrix.

  
  

Page 16 of 32 

 S09-367 : GWK 

 
  
  

	15.2	Termination by Stanford. 

  

	 	(A)	Stanford may also terminate this Agreement if ImmuMetrix: 

  

	 	(1)	is delinquent on any report or payment; 

  

	 	(2)	is not diligently developing and commercializing Licensed Product; 

  

	 	(3)	misses a milestone described in Appendix A; 

  

	 	(4)	is in breach of any provision; or 

  

	 	(5)	provides any false report. 

  

	 	(B)	Termination under this Section 15.2 will take effect 30 days after written notice by Stanford specifying the nature of the default or breach unless ImmuMetrix remedies the problem in that 30-day period.
Notwithstanding the foregoing, if ImmuMetrix disputes any such default or breach in writing within such 30-day period, Stanford shall not have the right to terminate this Agreement unless and until the arbitrator determines in a written decision
delivered to the parties under Section 17 below, that such default or breach occurred, and ImmuMetrix fails to cure such default or breach within 30 days after such determination. Each party shall use reasonable efforts to conclude such
arbitration within thirty (30) days of the initiation of such arbitration. 

  

	15.3	Surviving Provisions. Surviving any termination or expiration are: 

  

	 	(A)	ImmuMetrix’s obligation to pay royalties accrued or accruable; 

  

	 	(B)	any claim of ImmuMetrix or Stanford, accrued or to accrue, because of any breach or default by the other party; 

  

	 	(C)	the provisions of Articles 8, 9, 10 and 19.4 and any other provision that by its nature is intended to survive; and 

  

	 	(D)	any sublicense granted hereunder, provided that the sublicensee agrees in writing to be bound by the applicable terms of this Agreement. 

 

	16	ASSIGNMENT 

  

	16.1	Permitted Assignment by ImmuMetrix. Subject to Section 16.3, ImmuMetrix may assign this Agreement as part of a sale or change of control, regardless of whether such a sale or change of control occurs
through an asset sale, stock sale, merger or other combination, or any other transfer of: 

  

	 	(A)	ImmuMetrix’s entire business; or 

  

	 	(B)	that part of ImmuMetrix’s business that exercises all rights granted under this Agreement. 

  
  

Page 17 of 32 

 ***Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
 S09-367 : GWK 
  

 
  

	16.2	Any Other Assignment by ImmuMetrix. Any other attempt to assign this Agreement by ImmuMetrix is null and void. 

  

	16.3	Conditions of Assignment. Prior to any assignment, the following conditions must be met: 

  

	 	(A)	ImmuMetrix must give Stanford 30 days prior written notice of the assignment, including the new assignee’s contact information; and 

 

	 	(B)	the new assignee must agree in writing to Stanford to be bound by this Agreement; and 

  

	 	(C)	Stanford must have received a $[***] assignment fee. 

  

	16.4	After the Assignment. Upon a permitted assignment of this Agreement pursuant to Article 16, ImmuMetrix will be released of liability under this Agreement and the term “ImmuMetrix” in this
Agreement will mean the assignee. 

  

	16.5	Bankruptcy. In the event of a bankruptcy, assignment is permitted only to a party that can provide adequate assurance of future performance, including diligent development and sales, of Licensed Product.

  

	17	DISPUTE RESOLUTION 

  

	17.1	Dispute Resolution by Arbitration. Apart from any controversy or claim pertaining to HHMI’s rights under Article 10 or otherwise under this Agreement, any dispute between the parties regarding any
payments made or due under this Agreement will be settled by arbitration in accordance with the Licensing Agreement Arbitration Rules of the American Arbitration Association. The parties are not obligated to settle any other dispute that may arise
under this Agreement by arbitration. 

  

	17.2	Request for Arbitration. Either party may request such arbitration. Stanford and ImmuMetrix will mutually agree in writing on a third party arbitrator within 30 days of the arbitration request. The
arbitrator’s decision will be final and nonappealable and may be entered in any court having jurisdiction. 

  

	17.3	Discovery. The parties will be entitled to discovery as if the arbitration were a civil suit in the California Superior Court. The arbitrator may limit the scope, time, and issues involved in discovery.

  

	17.4	Place of Arbitration. The arbitration will be held in Stanford, California unless the parties mutually agree in writing to another place. 

 

	17.5	Patent Validity. Any dispute regarding the validity of any Licensed Patent shall be litigated in the courts located in Santa Clara County, California, and the parties agree not to challenge personal
jurisdiction in that forum. 

  
  

Page 18 of 32 

 S09-367 : GWK 

 
  

	18	NOTICES 

  

	18.1	Legal Action. ImmuMetrix will provide written notice to Stanford at least three months prior to bringing an action seeking to invalidate any Licensed Patent or a declaration of non-infringement. ImmuMetrix
will include with such written notice an identification of all prior art it believes invalidates any claim of the Licensed Patent. 

  

	18.2	All Notices. All notices under this Agreement are deemed fully given when written, addressed, and sent as follows: 

All general notices to ImmuMetrix are mailed to: 

ImmuMetrix, Inc. 

Attention: CEO/President 

Address: 

     

Email: 

With a copy (which shall not constitute notice) to: 

Wilson Sonsini Goodrich & Rosati PC 

Attention: Kenneth A. Clark, Esq. 

Address: 650 Page Mill Road 

Palo Alto, CA 94304 

Email: kclark@wsgr.com 

All financial invoices to ImmuMetrix (i.e., accounting contact) are e-mailed to: 

Name: Bruce Hironaka 

Email: 
 All
progress report invoices to ImmuMetrix (i.e., technical contact) are e-mailed to: 
 Name: Bruce Hironaka 

Email: 
 All
general notices to Stanford are e-mailed or mailed to: 
 Office of Technology Licensing 

     

     

     

All payments to Stanford are mailed to: 

Stanford University 

Office of Technology Licensing 

  
  

Page 19 of 32 

 S09-367 : GWK 

 
  
  

 
      

     

     

All progress reports to Stanford are e-mailed or mailed to: 

Office of Technology Licensing 

     

     

     

Either party may change its address with written notice to the other party. 

 

	19	MISCELLANEOUS 

  

	19.1	Waiver. No term of this Agreement can be waived except by the written consent of the party waiving compliance. 

  

	19.2	Choice of Law. This Agreement and any dispute arising under it is governed by the laws of the State of California, United States of America, applicable to agreements negotiated, executed, and performed
within California. 

  

	19.3	Exclusive Forum. The state and federal courts having jurisdiction over Stanford, California, United States of America, provide the exclusive forum for any court action between the parties relating to this
Agreement. ImmuMetrix submits to the jurisdiction of such courts, and waives any claim that such a court lacks jurisdiction over ImmuMetrix or constitutes an inconvenient or improper forum. 

 

	19.4	Third Party Beneficiary. HHMI is not a party to this Agreement and has no liability to any licensee or user of any technology covered by this Agreement, but HHMI is an intended third-party beneficiary of
this Agreement and certain of its provisions are for the benefit of and are enforceable by HHMI in its own name. 

  

	19.5	Headings. No headings in this Agreement affect its interpretation. 

  

	19.6	Electronic Copy. The parties to this document agree that a copy of the original signature (including an electronic copy) may be used for any and all purposes for which the original signature may have been
used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the absence of an original signature. 

 

	19.7	Entire Agreement. This Restated Agreement (including the exhibits attached hereto) constitutes the entire agreement between the parties relating to its subject matter and supersedes all prior and
contemporaneous agreements, understandings or representations, written or oral, between Stanford and ImmuMetrix with respect to such subject matter, including without limitation, the PCR Agreement and the Sequencing Agreement. 

  
  

Page 20 of 32 

 S09-367 : GWK 

 
  

The parties execute this Agreement in duplicate originals by their duly authorized officers or representatives. 

 

			
	THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
		
	Signature	 	 /s/ Katherine Ku

	Name	 	 Katharine Ku

	Title	 	 Director Office of Technology Licensing

	Date	 	 February 3, 2014

	
	ImmuMetrix, Inc.
		
	Signature.	 	 /s/ Bruce Hironaka

	Name	 	 Bruce Hironaka

	Title	 	 President

	Date	 	 February 4, 2014

  
  

Page 21 of 32 

 ***Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
 S09-367 : GWK 
  

 
 Appendix A 

 

	1.	[***] 

  

	2.	[***] 

  

	3.	[***] 

  

	4.	[***] 

  

	5.	[***] 

  

	6.	[***] 

  

	7.	[***] 

  

	8.	[***] 

  
  

Page 22 of 32 

 S09-367 : GWK 

 
  

Appendix B - Sample Reporting Form 

Stanford Docket No. S 
 This report is provided pursuant to the
license agreement between Stanford University and (ImmuMetrix Name) 
 License Agreement Effective Date: 

Name(s) of Licensed Products being reported: 
  

					
	 Report Covering Period
	  			
	 Yearly Maintenance Fee
	  	$	 	  
	 Number of Sublicenses Executed
	  			
	 Gross Revenue
	  	$	 	  
	 Net Sales
	  	$	 	  
	 Royalty Calculation
	  			
	 Royalty Subtotal
	  	$	 	  
	 Credit
	  	$	 	  
	 Royalty Due
	  	$	 	  

 Comments: 

  
  

Page 23 of 32 

 S09-367 : GWK 

 
  

Appendix C — Licensed Patents 
  

									
	 Country
	  	 Title
	  	Serial
Number	  	File Date	  	Publication
Number
	Australia	  	NON-INVASIVE DIAGNOSIS OF GRAFT REJECTION IN ORGAN TRANSPLANT PATIENTS	  	2010315084	  	05-Nov-2010	  	2010315084
					
	Canada	  	NON-INVASIVE DIAGNOSIS OF GRAFT REJECTION IN ORGAN TRANSPLANT PATIENTS	  	2,779,750	  	05-Nov-2010	  	2779750
					
	China (People’s Republic)	  	NON-INVASIVE DIAGNOSIS OF GRAFT REJECTION IN ORGAN TRANSPLANT PATIENTS	  	20108006046
9.4	  	05-Nov-2010	  	102712954
					
	European Patent Convention	  	NON-INVASIVE DIAGNOSIS OF GRAFT REJECTION IN ORGAN TRANSPLANT PATIENTS	  	10829142.8	  	05-Nov-2010	  	2496720
					
	Hong Kong	  	NON-INVASIVE DIAGNOSIS OF GRAFT REJECTION IN ORGAN TRANSPLANT PATIENTS	  	13102099.1	  	05-Nov-2010	  	1175268
					
	Japan	  	NON-INVASIVE DIAGNOSIS OF GRAFT REJECTION IN ORGAN TRANSPLANT PATIENTS	  	2012-538027	  	05-Nov-2010	  	2013509883
					
	 Patent
 Cooperation Treaty
	  	NON-INVASIVE DIAGNOSIS OF GRAFT REJECTION IN ORGAN TRANSPLANT PATIENTS	  	US2010/0556
04	  	05-Nov-2010	  	2011057061
					
	United Kingdom	  	NON-INVASIVE DIAGNOSIS OF GRAFT REJECTION IN ORGAN TRANSPLANT PATIENTS	  	1209978.4	  	05-Nov-2010	  	2488289
					
	United States of America	  	NON-INVASIVE DIAGNOSIS OF GRAFT REJECTION IN ORGAN TRANSPLANT PATIENTS	  	61/280,674	  	06-Nov-2009	  	N/A
					
	United States of America	  	NON-INVASIVE DIAGNOSIS OF GRAFT REJECTION IN ORGAN TRANSPLANT PATIENTS	  	13/508,318	  	19-Jul-2012	  	20120295810

  
  

Page 24 of 32 

 S09-367 : GWK 

 
  

Appendix D- Technology 
 1.
Algorithms and software code 
 2. sample preparation, per and sequencing protocols 

3. raw sequencing data to date of license execution 

4. patient records to date of license execution subject to IRB approval if needed 

5. unpublished data and manuscripts 

6. plasma, blood and tissue samples collected to date to permit ImmuMetrix to independently reproduce the results Stanford has obtained 

7. any other information or technology provided by Stanford to ImmuMetrix. 

  
  

Page 25 of 32 

 S09-367 : GWK 

 
  

Appendix E- Stock Purchase Agreement 

IMMUMETRIX, INC. 

COMMON STOCK PURCHASE AGREEMENT 
 This
Common Stock Purchase Agreement (the “Agreement”) is entered into by and between ImmuMetrix, Inc. (the “Company”) and
                    (the “Purchaser”) as of             , 2013 (the
“Effective Date”). 
 1 Sale of Shares. The Company will issue and sell to the Purchaser
            shares of the Company’s fully paid and nonassessable Common Stock (the “Shares”) pursuant to Section 7.16 of that certain Amended and Restated
Exclusive Agreement dated                     by and between the Purchase and the Company (the “License Agreement”). 

2 Closing; Delivery. 
 2.1
Closing. The closing of the purchase and sale of the Shares to the Purchaser hereunder shall be held at the offices of Wilson Sonsini Goodrich and Rosati, 650 Page Mill Road, Palo Alto, California 94304-1050 on the Effective Date (the
“Closing”). The Closing shall be contingent upon the Purchaser executing and delivering the License. Within a reasonable time after the Closing, the Company will issue a stock certificate, registered in the name of the Purchaser,
reflecting the Shares. 
 2.2 Delivery. At the Closing, the Company will deliver to the Purchaser a certificate representing the
Shares against the execution and delivery to the company of the License Agreement by Purchaser. If the Purchaser is not in attendance at the Closing, such delivery shall be via U.S. mail to the address shown under the Purchaser’s name on the
signature page to this Agreement. 
 3 Company Representations. The Company hereby represents and warrants to the Purchaser as of the
date hereof as follows: 
 3.1 Organization and Standing. The Company is a corporation duly organized, validly existing, and in good
standing under the laws of the State of Delaware. The Company has all requisite corporate power and authority to own and operate its properties and assets and to carry on its business as presently conducted. 

3.2 Corporate Power. The Company has all requisite legal and corporate power to execute and deliver this Agreement, to sell and issue
the Shares hereunder, and to carry out and perform its obligations under the terms of this Agreement. 
 3.3 Authorization. All
corporate action on the part of the Company, its officers, directors and stockholders necessary for the authorization, execution, delivery and performance by the Company of this Agreement, the authorization, issuance, sale and delivery of the
Shares, and the performance of the Company’s obligations hereunder has been taken or will be taken prior to the Closing. This Agreement, when executed and delivered by the Company, shall constitute a valid and legally binding obligation of the
Company enforceable in accordance with its respective terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors and rules of law governing specific performance, injunctive relief or other equitable
remedies. The Shares, when issued in compliance with the provisions of 

  
  

Page 26 of 32 

 S09-367 : GWK 

 
  

this Agreement, will be validly issued, fully paid and nonassessable, and the Shares will be free of any liens or encumbrances created by the Company; provided, however, that the Shares may be
subject to restrictions on transfer under applicable securities laws as set forth herein. 
 4 Purchaser Representations, Warranties and
Covenants. In connection with the purchase of the Shares, the Purchaser represents and warrants to the Company as follows: 
 4.1
The Purchaser is aware of the Company’s business affairs and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision to acquire the securities. The Purchaser is purchasing
these securities for investment for the Purchaser’s own account only and not with a view to, or for resale in connection with, any “distribution” thereof within the meaning of the Securities Act of 1933 (the “Securities
Act”). The Purchaser is an “accredited investor” within the meaning of SEC Rule 501 of Regulation D, as presently in effect. 

4.2 The Purchaser understands that the securities have not been registered under the Securities Act by reason of a specific exemption
therefrom, which exemption depends upon, among other things, the bona fide nature of the Purchaser’s investment intent as expressed herein. In this regard, the Purchaser understands that, in view of the Securities and Exchange Commission
(“Commission”), the statutory basis for such exemption may not be present if the Purchaser’s representations meant that the Purchaser’s present intention was to hold these securities for a minimum capital gains
period under the tax statutes, for a deferred sale, for a market rise, for a sale if the market does not rise, or for a year or any other fixed period in the future. 

4.3 The Purchaser further acknowledges and understands that the securities must be held indefinitely unless they are subsequently registered
under the Securities Act or an exemption from such registration is available. The Purchaser further acknowledges and understands that the Company is under no obligation to register the securities. The Purchaser understands that the certificate
evidencing the securities will be imprinted with a legend which prohibits the transfer of the securities unless they are registered or such registration is not required in the opinion of counsel for the Company. 

4.4 The Purchaser is aware of the adoption of Rule 144 by the Commission, promulgated under the Securities Act, which permits limited public
resale of securities acquired in a non-public offering subject to the satisfaction of certain conditions. 
 4.5 The Purchaser further
acknowledges that in the event all of the requirements of Rule 144 are not met, compliance with Regulation A or some other registration exemption will be required; and that although Rule 144 is not exclusive, the staff of the Commission has
expressed its opinion that persons proposing to sell private placement securities other than in a registered offering and other than pursuant to Rule 144 will have a substantial burden of proof in establishing that an exemption from registration is
available for such offers or sales and that such persons and the brokers who participate in the transactions do so at their own risk. 
 4.6
The Purchaser understands that the share certificate evidencing the Shares issued hereunder shall be endorsed with the following legends: 

(A) THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE

  
  

Page 27 of 32 

 S09-367 : GWK 

 
  

SALEOR DISTRIBUTION THEREOF. THES ECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE
TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR, IN THE OPINION OF COUNSEL SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT. 

(B) THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER, A RIGHT OF FIRST REFUSAL AND A LOCK-UP PERIOD
IN THE EVENT OF A PUBLIC OFFERING HELD BY THE ISSUER OR ITS ASSIGNEE(S) AS SET FORTH IN THE STOCK PURCHASE AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER.
SUCH TRANSFER RESTRICTIONS, RIGHT OF FIRST REFUSAL AND LOCK-UP PERIOD ARE BINDING ON TRANSFEREES OF THESE SHARES. 
 (C) Any legend
required to be placed thereon by applicable federal state securities laws, or the terms of this Agreement. 
 5 Market Standoff
Covenant. Purchaser shall not sell or otherwise transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, of any Common Stock (or other
securities) of the Company held by Purchaser (other than those included in the registration) during the period from the filing of the registration statement for the Company’s Initial Public Offering filed under the Securities Act that includes
securities to be sold on behalf of the Company to the public in an underwritten public offering under the Securities Act through the end of the one hundred and eighty (180) day period following the effective date of the registration statement
(or such other period as may be requested by the Company or an underwriter to accommodate regulatory restrictions on (i) the publication or other distribution of research reports and (ii) analyst recommendations and opinions, including,
but not limited to, the restrictions contained in NASD Rule 2711(0(4) or NYSE Rule 472(0(4), or any successor provisions or amendments thereto), provided that all officers and directors of the Company are bound by and have entered into similar
agreements and the Company uses all reasonable efforts to have all holders of at least one percent (1%) of the Company’s voting securities be bound by and enter into similar agreements. The obligations described in this Section 5
shall not apply to a registration relating solely to employee benefit plans on Form S-1 or Form S-8 or similar forms that may be promulgated in the future, or a registration relating solely to a transaction on Form S-4 or similar forms that may be
promulgated in the future. The Company may impose stop-transfer instructions and may stamp each such certificate with the second legend set forth in Section 4.6 with respect to the shares of Common Stock (or other securities) subject to the
foregoing restriction until the end of such one hundred and eighty (180) day (or other) period. Purchaser agrees to execute a market standoff agreement with said underwriters in customary form consistent with the provisions of this
Section 5. 

  
  

Page 28 of 32 

 S09-367 : GWK 

 
  

6 Company’s Right of First Refusal. Before any Shares acquired by the Purchaser pursuant to this Agreement (or any beneficial
interest in such Shares) may be sold, gifted, transferred, encumbered or otherwise disposed of in any way (whether by operation of law or otherwise) by the Purchaser or any subsequent transferee (each a “Holder”), such Holder must
first offer such Shares or beneficial interest to the Company and/or its assignee(s) as follows: 
 6.1 Notice of Proposed Transfer.
The Holder shall deliver to the Company a written notice stating: (a) the Holder’s bona fide intention to sell or otherwise transfer the Shares; (b) the name of each proposed transferee; (c) the number of Shares to be transferred
to each proposed transferee; (d) the bona fide cash price or other consideration for which the Holder proposes to transfer the Shares; and (e) that by delivering the notice, the Holder offers all such Shares to the Company and/or its
assignee(s) pursuant to this Section and on the same terms described in the notice. 
 6.2 Exercise of Right of First Refusal. At any
time within 30 days after receipt of the Holder’s notice, the Company and/or its assignee(s) may, by giving written notice to the Holder, elect to purchase all, but not less than all, of the Shares proposed to be transferred to any one or more
of the proposed transferees, at the purchase price determined in accordance with Section 6.3. 
 6.3 Purchase Price. The
purchase price for the Shares purchased by the Company and/or its assignee(s) under this Section shall be the price listed in the Holder’s notice. If the price listed in the Holder’s notice includes consideration other than cash, the cash
equivalent value of the non-cash consideration shall be determined by the Board of Directors of the Company in its sole discretion. 
 6.4
Payment. Payment of the purchase price shall be made, at the option of the Company and/or its assignee(s), in cash (by check), by cancellation of all or a portion of any outstanding indebtedness of the Holder to the Company and/or its
assignee(s), or by any combination thereof within 30 days after receipt by the Company of the Holder’s notice (or at such later date as is called for by such notice). 

6.5 Holder’s Right to Transfer. If all of the Shares proposed in the notice to be transferred to a given proposed transferee are
not purchased by the Company and/or its assignee(s) as provided in this Section, then the Holder may sell or otherwise transfer such Shares to that proposed transferee, provided that: (a) the transfer is made only on the terms provided for in
the notice, with the exception of the purchase price, which may be either the price listed in the notice or any higher price; (b) such transfer is consummated within 60 days after the date the notice is delivered to the Company; (c) the
transfer is effected in accordance with any applicable securities laws, and if requested by the Company, the Holder shall have delivered an opinion of counsel acceptable to the Company to that effect; and (d) the proposed transferee agrees in
writing that the provisions of this Section shall continue to apply to the transferred Shares in the hands of such proposed transferee. If any Shares described in a notice are not transferred to the proposed transferee within the period provided
above, then before any such Shares may be transferred, a new notice shall be given to the Company, and the Company and/or its assignees shall again be offered the right of first refusal described in this Section. 

6.6 Exception for Certain Transfers. Notwithstanding anything to the contrary contained elsewhere in this Section, the transfer of any
or all of the Shares by the Purchaser to his spouse, ex-spouse, domestic partner, lineal descendant or antecedent, brother or sister, the adopted child or adopted grandchild, or the spouse or domestic partner of any child, adopted child, grandchild
or adopted grandchild of the Purchaser, or to one or more trusts, retirement accounts, or other estate planning vehicles for the exclusive benefit of Purchaser or those members of Purchaser’s family specified in this Section, shall be exempt
from the provisions of this Section; provided that, in each such case, the transferee(s) shall agree in writing to receive and hold the Shares so transferred subject to all of the provisions of this Agreement, including but not limited to this
Section, and there shall be no further transfer of such Shares except in accordance with the terms of this Section. 

  
  

Page 29 of 32 

 S09-367 : GWK 

 
  

6.7 Termination of Right of First Refusal. The right of first refusal contained in this Section shall terminate as to all Shares
purchased hereunder upon the earlier of: (i) the closing date of the first sale of Common Stock of the Company to the general public pursuant to a registration statement filed with and declared effective by the Securities and Exchange
Commission under the Securities Act, as amended, and (ii) the closing date of a change of control transaction pursuant to which the holders of the outstanding voting securities of the Company receive securities of a class registered pursuant to
Section 12 of the Securities Exchange Act of 1934, as amended. 
 7 Miscellaneous. 

7.1 Governing Law. This Agreement shall be governed by and construed under the laws of the State of California. 

7.2 Finder’s Fee. Each party represents that it neither is nor will be obligated for any finder’s fee or commission in
connection with this transaction. The Purchaser and the Company agree to indemnify and hold harmless the other party from any liability for any commission or compensation in the nature of a finder’s fee (and the costs and expenses of defending
against such liability or asserted liability) for which the Purchaser or the Company is responsible. 
 7.3 Successors and Assigns.
Except as otherwise expressly provided, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors, and administrators of the parties. 

7.4 Entire Agreement. This Agreement, any exhibits thereto and any other documents delivered pursuant to this Agreement constitute the
full and entire understanding and agreement among the parties with regard to the subjects hereof and no party shall be liable or bound to any other party in any manner by any representations, warranties, covenants, or agreements except as
specifically set forth herein or therein. Nothing in this Agreement, express or implied, is intended to confer upon any third party any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided
herein. 
 7.5 Severability. In case any provision of this Agreement becomes or is declared by a court of competent jurisdiction to
be unenforceable, this Agreement shall continue in full force and effect without said provision; provided, however, that no such severability shall be effective if it materially changes the economic benefit of this Agreement to any party. 

7.6 Amendment and Waiver. Any term of the Agreement may be amended and the observance of any term of the Agreement may be waived
(either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the Purchaser. Any amendment or waiver effected in accordance with this Section shall be binding upon each
holder of any Shares purchased under the Agreement at the time outstanding, each future holder of all such securities and the Company. 

7.7 Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to the Purchaser or any subsequent
holder, of any Shares upon any breach, default or noncompliance of the Company under this Agreement shall impair any such right, power, or remedy, nor shall it be construed to be a waiver of any such breach, default or noncompliance, or any
acquiescence therein, or of any similar breach, default or noncompliance thereafter occurring. 

  
  

Page 30 of 32 

 S09-367 : GWK 

 
  

7.8 Notices. All notices and other communications required or permitted hereunder shall be in writing and shall be deemed effectively
given upon personal delivery or upon deposit with the United States Post Office, by first class mail, postage prepaid, addressed: (a) if to the Purchaser, at the Purchaser’s address as set forth on the signature page to this Agreement, or
at such other address as the Purchaser shall have furnished to the Company in writing, or (b) if to the Company, at its address as set forth on the signature page to this Agreement, or at such other address as the Company shall have furnished
to the Purchaser in writing. 
 7.9 Titles and Subtitles. The titles of the sections of this Agreement are for convenience of
reference only and are not to be considered in construing this Agreement. 
 7.10 Counterparts. This Agreement may be executed in any
number of counterparts, each of which is an original, and all of which together shall constitute one instrument. 

  
  

Page 31 of 32 

 S09-367 : GWK 

 
  

The foregoing Agreement is hereby confirmed and accepted by the Company as of the date first written above. 

COMPANY: 

IMMUMETRIX, INC 
  

			
	By:	 	  

	Print:	 	  

	Title:	 	  

	Address:
	  

	  

	
	PURCHASER:
	
	[            ]
		
	By:	 	  

	Print:	 	  

	Title:	 	  

	Address:
	  

	  

  
  

Page 32 of 32EX-4.1

 Exhibit 4.1 

MAVENIR SYSTEMS, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

July 15, 2014 

 TABLE OF CONTENTS 

 

					
	 	  	Page	 
	 1. Registration Rights
	  	 	1	  
	 1.1      Definitions
	  	 	1	  
	 1.2      Request for Registration
	  	 	3	  
	 1.3      Company Registration
	  	 	4	  
	 1.4      Obligations of the Company
	  	 	4	  
	 1.5      Furnish Information
	  	 	5	  
	 1.6      Expenses of Registrations
	  	 	6	  
	 1.7      Underwriting Requirements
	  	 	6	  
	 1.8      Delay of Registration
	  	 	7	  
	 1.9      Indemnification
	  	 	7	  
	 1.10    Reports Under Securities Exchange Act
	  	 	9	  
	 1.11    Form S-3 Registration
	  	 	9	  
	 1.12    Transfer or Assignment of Registration Rights
	  	 	11	  
	 1.13    Limitations on Subsequent Registration Rights
	  	 	11	  
	 1.14    “Market Stand-Off” Agreement
	  	 	11	  
	 1.15    Termination of Registration Rights
	  	 	12	  
	 1.16    Waiver
	  	 	12	  
		
	 2. [Reserved]
	  	 	13	  
		
	 3. [Reserved]
	  	 	13	  
		
	 4. Legend
	  	 	13	  
		
	 5. Miscellaneous
	  	 	13	  
	 5.1      Governing Law
	  	 	13	  
	 5.2      Waivers and Amendments
	  	 	13	  
	 5.3      Binding Effect
	  	 	13	  
	 5.4      Entire Agreement
	  	 	14	  
	 5.5      Notices
	  	 	14	  
	 5.6      Interpretation
	  	 	14	  
	 5.7      Severability
	  	 	14	  
	 5.8      Aggregation of Stock
	  	 	14	  
	 5.9      Counterparts
	  	 	15	  
	 5.10    Telecopy Execution and Delivery
	  	 	15	  
	 5.11    Amendment and Restatement of Prior Agreement
	  	 	15	  
	 5.12    Confidentiality
	  	 	15	  

 Schedules: 
  

					
	A	  	—	  	Schedule of Investors
	B	  	—	  	Schedule of Common Holders

 Exhibits 
  

					
	A	  	—	  	Adoption Agreement

  
 i 

 MAVENIR SYSTEMS, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of July 15, 2014, by and among
Mavenir Systems, Inc., a Delaware corporation (the “Company”), and the individuals and entities listed on Schedule A hereto (each, an “Investor” and collectively, the “Investors”) and certain
holders of the Company’s Common Stock listed on Schedule B hereto (each, a “Common Holder” and collectively, the “Common Holders”). This Agreement amends, supersedes and replaces the Company’s
Amended and Restated Investors’ Rights Agreement, dated May 26, 2011 (the “Prior Agreement”). 
 R E C I T A L
S 
 WHEREAS, in connection with the Company’s Series E Preferred Stock financing, the Company, the Investors and the Common
Holders entered into the Prior Agreement; 
 WHEREAS, the Company completed its initial public offering of the Common Stock in November
2013, and in connection therewith all of the shares of the Company’s Series E Convertible Preferred Stock, Series D Convertible Preferred Stock, Series C Convertible Preferred Stock, Series B Convertible Preferred Stock, and Series A
Convertible Preferred Stock converted into shares of Common Stock; and 
 WHEREAS, the Existing Investors are holders of at least a majority
of the Registrable Securities (as defined in the Prior Agreement), and desire to amend and restate the Prior Agreement in its entirety to, among other things, (1) waive applicability of this Agreement to an offering of Common Stock by the
Company; and (2) make certain other updates and changes reflected herein; and (3) accept the rights created pursuant to this Agreement in lieu of the rights granted to them under the Prior Agreement. 

NOW, THEREFORE, in consideration of the mutual promises and covenants set forth herein, the Existing Investors hereby agree that the Prior
Agreement shall be superseded and replaced in its entirety by this Agreement, and the parties hereto further agree as follows: 
 1.
Registration Rights.
 1.1 Definitions. As used in this Agreement, the following terms shall have the meanings set forth below:

 (a) “Capital Stock” means any and all shares of Common Stock and Preferred Stock and all other shares, interests,
participation rights or other equivalents in the equity interests in the Company. 
 (b) “Commission” means the United
States Securities and Exchange Commission. 
 (c) “Common Stock” means the Company’s common stock, par value $0.001
per share. 

 (d) “Conversion Stock” means the shares of Common Stock issued or issuable upon
conversion of the Shares. 
 (e) “Exchange Act” means the Securities Exchange Act of 1934, as amended. 

(f) “Form S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the
Securities Act subsequently adopted by the Commission that permits inclusion or incorporation of substantial information by reference to other documents filed by the Company with the Commission. 

(g) “Holder” means any person owning or having the right to acquire Registrable Securities or any assignee thereof in
accordance with Section 1.12. 
 (h) “Preferred Stock” means any class or series of the Company’s preferred
stock, par value $0.001 per share. 
 (i) The terms “register,” “registered” and
“registration” refer to a registration effected by preparing and filing a registration statement or similar document in compliance with the Securities Act or any other applicable law of any other jurisdiction, and the declaration or
ordering of effectiveness of such registration statement or document. 
 (j) “Registrable Securities” means (i) the
Conversion Stock and (ii) any of the Company’s Common Stock issued as (or issuable upon the conversion or exercise of any warrant, note or other security that is issued as) a dividend or other distribution with respect to, or in exchange
for, or in replacement of, the shares referenced in (i) above; provided, however, that Registrable Securities shall not include any shares of Common Stock which have previously been registered, which have been sold to the public either
pursuant to a registration statement or Rule 144, or which have been sold in a private transaction in which the transferor’s rights under this Section 1 are not assigned. 

(k) “Rule 144” means Rule 144 as promulgated by the Commission under the Securities Act, as such Rule may be amended from
time to time, or any similar successor rule that may be promulgated by the Commission. 
 (l) “Rule 145” means Rule 145 as
promulgated by the Commission under the Securities Act, as such Rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission. 

(m) “Securities Act” means the Securities Act of 1933, as amended. 

(n) “Shares” means the shares of the Company’s Series A Preferred Stock, $0.001 par value per share, Series B Preferred
Stock, $0.001 par value per share, Series C Preferred Stock, $0.001 par value per share, Series D Preferred Stock, $0.001 par value per share and Series E Preferred Stock, $0.001 par value per share. 

  
 2 

 1.2 Request for Registration. 

(a) Subject to the conditions of this Section 1.2, if the Company shall receive at any time after the earlier of (i) one hundred
eighty days after the closing of a firm commitment underwritten public offering pursuant to an effective registration statement on Form S-1 under the Securities Act covering the offer and sale of Common Stock to the public for the account of the
Company and (ii) the third anniversary of the date of this Agreement, a written request from the Holders of a majority of the Registrable Securities then outstanding that the Company effect a registration under the Securities Act with respect
to at least a majority of the Registrable Securities then outstanding (the “Initiating Holders”), then the Company shall (x) give written notice of such request to all Holders within ten (10) calendar days of the date such
request is given and (y) use its best efforts to effect as soon as practicable (and in any event within ninety (90) calendar days of the date such request is given) the registration under the Securities Act of all Registrable Securities
that the Holders request to be registered within twenty (20) calendar days of the date the Company’s notice referred to in this subsection 1.2(a) is given. 

(b) If the Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall
so advise the Company as a part of their request made pursuant to subsection 1.2(a) and the Company shall include such information in the written notice referred to in subsection 1.2(a). The underwriter will be selected by the Company and
shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include its Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such
underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as
provided in subsection 1.4(e)) enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting. Notwithstanding any other provision of this Section 1.2, if the underwriter advises
the Initiating Holders in writing that marketing factors require a limitation of the number of shares to be underwritten, then the Company shall so advise all Holders of Registrable Securities that would otherwise be underwritten pursuant hereto,
and the number of shares of Registrable Securities that may be included in the underwriting shall be allocated among all Holders electing to include shares in the underwriting, including the Initiating Holders, in proportion (as nearly as
practicable) to the amount of Registrable Securities requested by each such Holder to be included in such underwriting; provided, however, that the number of shares of Registrable Securities to be included in such underwriting shall not be
reduced unless all other securities (including those to be sold for the Company’s account) are first entirely excluded from the underwriting. 

(c) Notwithstanding the foregoing, if the Company shall furnish to the Initiating Holders a certificate signed by the Company’s Chief
Executive Officer or President stating that in the good faith judgment of the Company’s Board of Directors, such registration would be seriously detrimental to the Company and its stockholders and that it is, therefore, essential to defer
taking action with respect to such registration, the Company shall have the right to defer taking action with respect to such filing for a period of not more than one hundred twenty (120) calendar days after the date the request of the
Initiating Holders is given; provided, however, that the Company may not utilize this right more than once in any twelve (12) month period; provided, further, that the Company shall not register any securities for the account of
itself or any other stockholder during such period other than (i) a registration statement relating either to the sale of securities to employees of the Company pursuant to a stock option, stock

  
 3 

 
purchase, stock incentive or stock appreciation plan or arrangement, (ii) a transaction pursuant to Rule 145 promulgated under the Securities Act, (iii) a registration in which the only
Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered, or (iv) a registration in connection the initial public offering of the Company’s securities (provided that, in the
case of (iv), the Company has complied with its obligations under Section 1.3). 
 (d) In addition, the Company shall not be obligated
to effect, or to take any action to effect, any registration pursuant to this Section 1.2: 
 (i) after the Company has effected three
(3) registrations pursuant to this Section 1.2 and such registrations have been declared or ordered effective; 
 (ii) during the
period starting with the date sixty (60) calendar days prior to the Company’s good faith estimate of the date of filing of, and ending on a date one hundred eighty (180) calendar days after the effective date of, any registration
statement pertaining to a public offering of securities for the Company’s account; provided, that the Company is actively employing its best efforts to cause such registration statement to be effective; 

(iii) in any particular jurisdiction in which the Company would be required to qualify to do business or to execute a general consent to
service of process in effecting such registration, qualification or compliance unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; or 

(iv) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant
to a request made pursuant to Section 1.11. 
 1.3 Company Registration. If the Company proposes to register any of its stock or
other securities either for its own account or the account of a stockholder or stockholders exercising their respective demand registration rights (other than (i) a registration pursuant to Sections 1.2 or 1.11, (ii) a registration
relating solely to employee benefit or similar plans, (iii) a registration relating to a Rule 145 transaction or (iv) a registration on any form which does not permit secondary sales or does not include substantially the same information
as would be required to be included in a registration statement covering the Registrable Securities), the Company shall, at such time, promptly give each Holder written notice of such registration. Upon the written request of each Holder given
within twenty (20) calendar days of the date such notice is given, the Company shall, subject to the provisions of Section 1.7, include in the registration all of the Registrable Securities that each such Holder has requested to be
registered. 
 1.4 Obligations of the Company. Whenever required under this Section 1 to effect the registration of any
Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
 (a) Prepare and file with the Commission a
registration statement with respect to such Registrable Securities and use its best efforts to cause such registration statement to become effective, and to keep such registration statement effective for a period of up to forty-five
(45) calendar days or any lesser period of time in the event the distribution described in the registration statement has been completed. 

  
 4 

 (b) Prepare and file with the Commission such amendments and supplements to such registration
statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement; 

(c) Furnish to the Holders such numbers of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements of
the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them; 

(d) Use its best efforts to register and qualify the securities covered by such registration statement under such other securities or blue sky
laws of such jurisdictions as shall be reasonably requested by the Holders; provided, that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service
of process in any such states or jurisdictions unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the managing underwriter(s) of such offering (each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement); 

(f) Notify each Holder of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto is
required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a
material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing; 

(g) Cause all such Registrable Securities registered pursuant hereunder to be listed on each securities exchange or nationally recognized
quotation system on which similar securities issued by the Company are then listed; and 
 (h) Provide a transfer agent and registrar for
all Registrable Securities registered pursuant hereunder and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration. 

1.5 Furnish Information. It shall be a condition precedent to the Company’s obligations to take any action pursuant to this
Section 1 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding such Holder, the Registrable Securities held by such Holder, and the intended method of
disposition of such securities as shall be reasonably required by the Company or the managing underwriters, if any, to effect the registration of such Holder’s Registrable Securities. 

  
 5 

 1.6 Expenses of Registrations. All expenses (other than underwriting discounts and
commissions) incurred in connection with registrations, filings or qualifications pursuant to Sections 1.2, 1.3 or 1.11, including (without limitation) all registration, filing and qualification fees, printer’s fees, accounting fees and
fees and disbursements of counsel for the Company (including fees and disbursements of counsel for the Company in its capacity as counsel to the selling Holders hereunder; but if Company counsel does not make itself available for this purpose, the
Company will pay the reasonable fees and disbursements of one counsel for the selling Holders) shall be borne by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding
begun pursuant to Sections 1.2 or 1.11 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all participating Holders shall bear such
expenses on a pro rata basis based on the number of Registrable Securities proposed to be registered by each such Holder), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one demand registration
pursuant to Section 1.2; provided further, however, that if at the time of such withdrawal, the Holders have learned of a material adverse change in the condition, business, or prospects of the Company and such material adverse change
was not known to the Holders at the time of their request and have withdrawn the request with reasonable promptness following disclosure by the Company of such material adverse change, then the Holders shall not be required to pay any of such
expenses and shall not forfeit their right to one (1) demand registration pursuant to Section 1.2; and provided further, that changes resulting solely from the condition of the stock market substantially equally affecting all
similarly situated companies shall not be deemed to be a material adverse change in the condition, business or prospects of the Company. Registrations effected pursuant to Section 1.11 shall not be counted as demands for registration or
registrations effected pursuant to Section 1.2 or 1.3, respectively. 
 1.7 Underwriting Requirements. If the registration
statement under which the Company gives notice under Section 1.3 is for an underwritten offering, the Company shall so advise the Holders. In such event, all Holders proposing to distribute their securities through such underwriting shall
(together with the Company as provided in subsection 1.4(e)) enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting. If the total amount of securities, including Registrable
Securities requested by stockholders to be included in such offering, exceeds the amount of securities sold other than by the Company that the underwriters determine in their sole discretion is compatible with the success of the offering, then the
Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters determine in their sole discretion will not jeopardize the success of the offering (the securities so
included to be apportioned pro rata among the selling stockholders according to the total amount of securities requested to be included therein by each such selling stockholder or in such other proportions as shall mutually be agreed to by such
selling stockholders), but in no event shall (i) the amount of securities of the selling Holders included in the offering be reduced unless the securities of all other selling stockholders included in the offering are entirely excluded and
(ii) the amount of securities of the selling Holders included in the offering be reduced below thirty percent (30%) of the total amount of securities included in such offering. For purposes of the preceding parenthetical concerning
apportionment, for any selling stockholder which is a Holder of Registrable Securities and which is a partnership, limited liability company or corporation, the partners (or retired partners), members (or retired members) and stockholders of 

  
 6 

 
such selling stockholder, or the estates and family members of any such partners (or retired partners), members (or retired members) or stockholders and any trusts for the benefit of any of the
foregoing persons shall be deemed to be a single “selling stockholder” and any pro rata reduction with respect to such “selling stockholder” shall be based upon the aggregate amount of shares carrying registration rights owned by
all entities and individuals included in such “selling stockholder” as defined in this sentence. 
 1.8 Delay of
Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this
Section 1. 
 1.9 Indemnification. 

(a) To the extent permitted by law, the Company will indemnify and hold harmless each Holder, its officers, directors, partners or former
partners, and members or former members, any underwriter (as defined in the Securities Act) for such Holder and each person, if any, who controls such Holder, its officers, directors, partners or former partners, and members or former members, or
underwriter within the meaning of the Securities Act or the Exchange Act (each an “Indemnified Person”), against any losses, claims, damages, or liabilities (joint or several) to which any of the foregoing persons may become subject
under the Securities Act, the Exchange Act or other federal or state or other applicable securities law, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any of the following
statements, omissions or violations (collectively, a “Violation”): (i) any untrue statement or alleged untrue statement of a material fact contained in a registration statement, including any preliminary prospectus or final
prospectus contained therein or any amendments or supplements thereto (collectively, the “Filings”); (ii) the omission or alleged omission to state in the Filings a material fact required to be stated therein, or necessary to
make the statements therein not misleading; or (iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any state or other applicable securities law or any rule or regulation promulgated under the
Securities Act, the Exchange Act or any state securities law; and the Company will pay, as incurred, any legal or other expenses reasonably incurred by any Indemnified Person in connection with investigating or defending any such loss, claim,
damage, liability or action; provided, however, that the indemnity agreement contained in this subsection 1.9(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability, or action if such settlement is
effected without the consent of the Company (which consent shall not be unreasonably withheld or delayed), nor shall the Company be liable to such Indemnified Person in any such case for any such loss, claim, damage, liability, or action to the
extent that it arises out of or is based upon a Violation that occurs in reliance upon and in conformity with written information furnished to the Company expressly for use in connection with such registration by an Indemnified Person. 

(b) To the extent permitted by law, each selling Holder will severally and not jointly indemnify and hold harmless the Company, each of its
directors, each of its officers, each person, if any, who controls the Company within the meaning of the Securities Act, any underwriter, any other Holder selling securities in such registration statement and any controlling person of any such
underwriter or other Holder, against any losses, claims, damages, or liabilities (joint or several) to which any of the foregoing persons may become subject under 

  
 7 

 
the Securities Act, the Exchange Act or other federal or state securities law insofar as such losses, claims, damages or liabilities (or actions in respect thereto) arise out of or are based upon
any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written information furnished by such Holder expressly for use in the registration statement in connection with
such Filings; and each such Holder will pay, as incurred, any legal or other expenses reasonably incurred by any person to be indemnified pursuant to this subsection 1.9(b) in connection with investigating or defending any such loss, claim,
damage, liability or action; provided, however, that the indemnity agreement contained in this subsection 1.9(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is
effected without the consent of the Holder (which consent shall not be unreasonably withheld or delayed); provided, however, in no event shall the obligations of any Holder under this subsection 1.9(b) exceed the net proceeds from the
shares of Registrable Securities sold in the offering and received by such Holder. 
 (c) Promptly after receipt by an indemnified party
under this Section 1.9 of notice of the commencement of any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 1.9, deliver
to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly
noticed, to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall
have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or
potential differing interests between such indemnified party and any other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such
action shall relieve such indemnifying party of liability to the indemnified party under this Section 1.9, but only to the extent such failure to deliver written notice is materially prejudicial to the indemnifying party’s ability to
defend such action. 
 (d) If the indemnification provided for in Section 1.9(a) and (b) is held by a court of competent
jurisdiction to be unavailable to an indemnified party with respect to any loss, claim, damage or expense referred to therein, then the indemnifying party in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid
or payable by such indemnified party as a result of such loss, claim, damage or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in
connection with the statements or omissions or alleged statements or omissions that resulted in such loss, liability, claim or expense as well as any other relevant equitable considerations. The relative fault of the indemnifying party and of the
indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’
relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. In no event shall any Holder be required to contribute an amount, when combined with any amounts paid pursuant to
Section 1.9(b), that exceeds the net proceeds from the shares of Registrable Securities sold in the offering and received by such Holder. 

  
 8 

 (e) The obligations of the Company and Holders under this Section 1.9 shall survive the
completion of any offering of Registrable Securities in a registration statement under this Section 1, and the termination of this Agreement. 

1.10 Reports Under Securities Exchange Act. With a view to making available the benefits of certain rules and regulations of the
Commission, including Rule 144, which may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company agrees to: 

(a) Make and keep public information available, as those terms are understood and defined in Rule 144 after the effective date of the first
registration statement filed by the Company for the offering of its securities to the general public; 
 (b) Take such action, including the
registration of its Common Stock under Section 12 of the Exchange Act, as is necessary to enable the Holders to utilize Form S-3 for the sale of their Registrable Securities, such action to be taken as soon as practicable after the end of the
fiscal year in which the first registration statement filed by the Company for the offering of its securities to the general public is declared effective; 

(c) File with the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and the
Exchange Act; and 
 (d) Furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) a
written statement by the Company that it has complied with the reporting requirements of Rule 144, the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a registrant
whose securities may be resold pursuant to Form S-3 (at any time after it so qualifies), (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (iii) such
other information as may be reasonably requested in availing any Holder of any rule or regulation of the Commission that permits the selling of any such securities without registration or pursuant to such form. 

1.11 Form S-3 Registration. 

(a) Subject to the conditions of this Section 1.11, if the Company shall receive from the Holders of a majority of the Registrable
Securities then outstanding a written request that the Company effect a registration on Form S-3 and any related qualification or compliance with respect to all or a part of the Registrable Securities owned by such Holder(s), then the Company shall
(a) promptly give written notice of the proposed registration, and any related qualification or compliance, to all other Holders and (b) use its best efforts to effect, as soon as practicable, such registration and all such qualifications
and compliances as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of the Registrable Securities specified in such request, together with all or such portion of the Registrable Securities of any
other Holder joining in such request as are specified in a written request given within fifteen (15) calendar days of the date the Company’s notice referred to in clause (a) of this sentence is given. 

  
 9 

 (b) If the Holders requesting registration pursuant to this Section 1.11 intend to
distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as part of their request made pursuant to this Section 1.11 and the Company shall include such information in the
written notice referred to in clause (a) of Section 1.11(a). The underwriter will be selected by the Company and shall be reasonably acceptable to a majority in interest of the Holders requesting registration. In such event, the right of
any Holder to include its Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent
provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided in Section 1.4(e)) enter into an underwriting agreement in customary form with the underwriter or
underwriters selected for such underwriting. Notwithstanding any other provision of this Section 1.11, if the underwriter advises the Holders requesting registration in writing that marketing factors require a limitation of the number of shares
to be underwritten, then the Holders requesting registration shall so advise all Holders of Registrable Securities that would otherwise be underwritten pursuant hereto, and the number of shares of Registrable Securities that may be included in the
underwriting shall be allocated among all Holders thereof, including the Holders requesting registration, in proportion (as nearly as practicable) to the amount of Registrable Securities requested by each such Holder to be included in such
underwriting; provided, however, that the number of shares of Registrable Securities to be included in such underwriting shall not be reduced unless all other Securities (including those to be sold for the Company’s account) are first
entirely excluded from the underwriting. 
 (c) Notwithstanding the foregoing, if the Company shall furnish to the Holder(s) requesting a
registration pursuant to this Section 1.11, a certificate signed by the Company’s Chief Executive Officer or President stating that in the good faith judgment of the Company’s Board of Directors, such registration would be seriously
detrimental to the Company and its stockholders and that it is, therefore, essential to defer taking action with respect to such registration, the Company shall have the right to defer taking action with respect to such filing for a period of not
more than one hundred twenty (120) calendar days after the date the request of the Holder(s) requesting a registration pursuant to this Section 1.11 is given; provided, however, that the Company shall not utilize this right more
than once in any twelve (12) month period. 
 (d) In addition, the Company shall not be obligated to effect, or to take any action to
effect, any registration pursuant to this Section 1.11: 
 (i) if Form S-3 is not available for such offering by the Holders; 

(ii) if the Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration, propose to
sell Registrable Securities and such other securities (if any) at an aggregate price to the public (net of underwriting discounts and commissions) of less than $10,000,000; 

  
 10 

 (iii) during the period starting with the date sixty (60) calendar days prior to the
Company’s good faith estimate of the date of filing of, and ending on a date one hundred eighty (180) calendar days after the effective date of, any registration statement pertaining to an underwritten public offering of securities for the
Company’s account; provided that the Company is actively employing its best efforts to cause such registration statement to be effective; or 

(iv) in any particular jurisdiction in which the Company would be required to qualify to do business or to execute a general consent to
service of process in effecting such registration, qualification or compliance unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act. 

1.12 Transfer or Assignment of Registration Rights. The rights to cause the Company to register Registrable Securities pursuant to this
Section 1 may be transferred or assigned, but only with all related obligations, by a Holder to a transferee or assignee who acquires at least 14,285 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock
dividends and combinations) from such transferring Holder; provided, that (a) the Company is furnished with written notice stating the name and address of such transferee or assignee and identifying the securities with respect to which
such registration rights are being transferred or assigned, (b) such transferee or assignee agrees in writing to be bound by and subject to the terms and conditions of this Agreement, including without limitation the provisions of
Section 1.14 and (c) such transfer or assignment shall be effective only if immediately following such transfer or assignment, the further disposition of such securities by the transferee or assignee is restricted under the Securities Act.

 1.13 Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the
prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company giving such holder or prospective holder any
registration rights, the terms of which are senior to, or in any manner inconsistent with the registration rights granted to the Holders hereunder. 

1.14 “Market Stand-Off” Agreement. Each Investor and Common Holder hereby agrees that, if requested by the managing
underwriter, it will not, without the prior written consent of the Company, during the period commencing on the date of the final prospectus relating to the Company’s initial public offering or any secondary public offering, as applicable, and
ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) calendar days in the case of an initial public offering and, solely in the case of a Common Holder, ninety
(90) calendar days in the case of any secondary public offering (or such other period as may be requested by the Company or managing underwriter to accommodate regulatory restrictions on (i) the publication or other distribution of
research reports and (ii) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto)) (i) lend, offer,
pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any securities of the
Company, including (without limitation) shares of Common Stock or any securities convertible 

  
 11 

 
into or exercisable or exchangeable for Common Stock (whether now owned or hereafter acquired) or (ii) enter into any swap or other arrangement that transfers to another, in whole or in
part, any of the economic consequences of ownership of any securities of the Company, including (without limitation) shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock (whether now owned or
hereafter acquired), whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of securities, in cash or otherwise. The foregoing covenants shall not apply to the sale of any shares by an Investor
or Common Holder to an underwriter pursuant to an underwriting agreement and shall only be applicable to the Investors and Common Holders if all the Company’s executive officers and directors enter into similar agreements. Each Investor and
Common Holder agrees to execute an agreement(s) reflecting (i) and (ii) above as may be requested by the managing underwriters at the time of the initial public offering or any secondary public offering (in the case of a Common Holder),
and further agrees that the Company may impose stop transfer instructions with its transfer agent in order to enforce the covenants in (i) and (ii) above. Any discretionary waiver or termination of the restrictions of any or all such
agreements by the Company shall apply to all Investors and Common Holders subject to such agreements pro rata based on the number of shares of stock or options to purchase shares of stock held by such Investors and Common Holders that are subject to
such agreements. The restrictions in this Section 1.14 shall not apply to transfers to affiliates of Investors or Common Holders or purchases made in the open market following the completion of any offering covered by this Section 1.14,
or, as to each Investor and Common Holder, to any resale public offerings in which such Investor or Common Holder is not selling shares of Common Stock for its own account. 

1.15 Termination of Registration Rights. No Holder shall be entitled to exercise any right provided for in this Section 1 after the
earlier of (i) November 13, 2018 or (ii) as to any Holder, on such date after November 13, 2013 at which the Company is subject to the reporting requirements of the Exchange Act and all shares of Registrable Securities held or
entitled to be held upon conversion by such Holder may be sold under Rule 144 of the Securities Act during any 90-day period free of the current public information, volume limitation, and manner of sale restrictions, and the Form 144 filing
requirements. 
 1.16 Waiver. In connection with the proposed public offering (the “Offering”) of the Common Stock
being made pursuant to a registration statement filed with the Commission on or about July 15, 2014, the Holders waive any and all rights pursuant to Section 1 hereto in connection with the Offering, including without limitation, rights to
register any shares, whether now owned or hereafter acquired, of the Company’s capital stock pursuant to Section 1.3 hereto, and any and all notice requirements contained in the Prior Agreement and this Agreement related thereto. 

  
 12 

 2. [Reserved]. 

3. [Reserved]. 
 4.
Legend. Each certificate representing the shares of Common Stock held by the Investors and by the Common Holders shall be endorsed with the following legend (the “Legend”): 

THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A LOCK-UP PERIOD FOLLOWING THE EFFECTIVE DATE OF A REGISTRATION STATEMENT OF THE
COMPANY FILED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AS SET FORTH IN THAT CERTAIN AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT BETWEEN THE COMPANY AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE
COMPANY’S PRINCIPAL OFFICE. SUCH LOCK-UP PERIOD IS BINDING ON TRANSFEREES OF THESE SHARES. 
 5. Miscellaneous. 

5.1 Governing Law. This Agreement shall be governed in all respects by the laws of the State of Delaware as such laws are applied to
agreements between Delaware residents entered into and to be performed entirely within Delaware, without regard to conflict of laws rules. 

5.2 Waivers and Amendments. This Agreement may be terminated and any term of this Agreement may be amended or waived (either generally
or in a particular instance and either retroactively or prospectively) with the written consent of the Company and Investors holding a majority of the Registrable Securities then outstanding (the “Major Investors”). The Company may
amend the schedules hereto from time to time to remove any holder whose rights have terminated pursuant to Section 1.15. Any termination, amendment or waiver effected in accordance with this Section 5.2 shall be binding upon each holder of
Registrable Securities then outstanding, each future holder of all such Registrable Securities, the Common Holders and the Company. 
 5.3
Binding Effect. In addition to any restriction on transfer that may be imposed by any other agreement by which any party hereto may be bound, this Agreement shall be binding upon the Investors and Common Holders and their respective permitted
transferees, heirs, executors, administrators, successors and assigns; provided, however, that the Company shall not effect any transfer of Capital Stock subject to this Agreement on its books or issue a new certificate for such
Capital Stock unless the transferee of such Capital Stock shall have executed and delivered an Adoption Agreement substantially in the form attached hereto as Exhibit A. Upon the execution and delivery of an Adoption Agreement by any
transferee, such transferee shall be deemed to be a party hereto as if such transferee’s signature appeared on the signature pages hereto. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the
parties to this Agreement or their respective successors and assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 

  
 13 

 5.4 Entire Agreement. This Agreement constitutes the full and entire understanding and
agreement among the parties with regard to the subject matter hereof, and no party shall be liable or bound to any other party in any manner by any warranties, representations or covenants except as specifically set forth herein. 

5.5 Notices. All notices and other communications required or permitted under this Agreement shall be in writing and shall be delivered
personally by hand or by courier, mailed by United States first-class mail, postage prepaid, or sent by facsimile directed (a) if to an Investor, at such Investor’s address or facsimile number set forth in the Company’s records, or at
such other address or facsimile number as such Investor may designate by ten (10) days’ advance written notice to the other parties hereto, (b) if to a Common Holder, at such Common Holder’s address or facsimile number set forth
in the Company’s records, or at such other address or facsimile number as such Common Holder may designate by ten (10) days’ advance written notice to the other parties hereto or (c) if to the Company, to its address or facsimile
number set forth on its signature page to this Agreement and directed to the attention of the President, or at such other address or facsimile number as the Company may designate by ten (10) days’ advance written notice to the other
parties hereto. All such notices and other communications shall be effective or deemed given upon personal delivery, on the date of mailing, or upon confirmation of facsimile transfer (or if to an overseas address, two (2) business days after
delivery to a recognized overseas air courier service). 
 5.6 Interpretation. The words “include,” “includes” and
“including” when used herein shall be deemed in each case to be followed by the words “without limitation.” The titles and subtitles used in this Agreement are used for convenience only and are not considered in construing or
interpreting this Agreement. 
 5.7 Severability. If any provision of this Agreement becomes or is declared by a court of competent
jurisdiction to be illegal, unenforceable or void, portions of such provision, or such provision in its entirety, to the extent necessary, shall be severed from this Agreement, and such court will replace such illegal, void or unenforceable
provision of this Agreement with a valid and enforceable provision that will achieve, to the extent possible, the same economic, business and other purposes of the illegal, void or unenforceable provision. The balance of this Agreement shall be
enforceable in accordance with its terms. 
 5.8 Aggregation of Stock. All shares of Registrable Securities held or acquired by a
Holder and its affiliated entities shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. For purposes of the foregoing, any shares of Registrable Securities held by a Holder that (X) is
a partnership, limited liability company or corporation shall be deemed to include shares held by (i) entities affiliated with such partnership, limited liability company or corporation, (ii) any partner (or retired partner), member (or
retired member) or stockholder of such partnership, limited liability company or corporation, (iii) the spouse, siblings, lineal descendants or ancestors of any such partner (or retired partner), member (or retired member) or stockholder,
(iv) the estate of any such partner 

  
 14 

 
(or retired partner), member (or retired member) or stockholder and (v) any custodian or trustee for the benefit of any such partner (or retired partner), member (or retired member) or
stockholder or the spouse, siblings, lineal descendants or ancestors of any such partner (or retired partner), member (or retired member) or stockholder or (Y) is an individual shall be deemed to include shares held by (i) the estate of
such individual or (ii) the spouse, siblings, lineal descendants or ancestors of such individual and any custodian or trustee for the benefit of any of the foregoing persons. 

5.9 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which
together shall constitute one instrument. 
 5.10 Telecopy Execution and Delivery. A facsimile, telecopy or other reproduction of this
Agreement may be executed by one or more parties hereto, and an executed copy of this Agreement may be delivered by one or more parties hereto by facsimile or similar electronic transmission device pursuant to which the signature of or on behalf of
such party can be seen, and such execution and delivery shall be considered valid, binding and effective for all purposes. At the request of any party hereto, all parties hereto agree to execute an original of this Agreement as well as any
facsimile, telecopy or other reproduction hereof. 
 5.11 Amendment and Restatement of Prior Agreement. Pursuant to Section 5.2
of the Prior Agreement, the Major Investors (as that term is defined in the Prior Agreement) hereby amend and restate the Prior Agreement on behalf of all Investors (as that term is defined in the Prior Agreement) with this Agreement, and any
Investor (as that term is defined in the Prior Agreement) who does not sign this Agreement shall be bound by the terms and conditions of this Agreement pursuant to Section 5.2 of the Prior Agreement as if that Investor (as that term is defined
in the Prior Agreement) had signed this Agreement. 
 5.12 Confidentiality. Each Investor and Common Holder party hereto agrees that
such person will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including
notice of the Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section 5.12 by such person),
(b) is or has been independently developed or conceived by such person without use of the Company’s confidential information, or (c) is or has been made known or disclosed to such person by a third party without a breach of any
obligation of confidentiality such third party may have to the Company; provided, however, that an Investor or Common Holder may disclose confidential information (i) to its attorneys, accountants, consultants, and other
professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; and (ii) as may otherwise be required by law, provided that such person promptly notifies the Company of such disclosure
and takes reasonable steps to minimize the extent of any such required disclosure. Each Investor and Common Holder acknowledges that confidential information obtained from the Company pursuant to the terms of this Agreement could be material,
non-public information and further acknowledges that he/she is aware of the restrictions imposed by the United States securities laws on the purchase or sale of securities by any person who has received material, non-public information from the
issuer of such securities 

  
 15 

 
and on the communication of such information to any other person when it is reasonably foreseeable that such other person is likely to purchase or sell such securities in reliance upon such
information. Accordingly, each Investor and Common Holder acknowledges and agrees that he/she has not and will not engage in any transactions in the Company’s securities while in possession of material, non-public information. 

[Remainder of page intentionally left blank.] 

  
 16 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year first set
forth above. 
  

			
	“Company”
	
	Mavenir Systems, Inc.
		
	By:	 	 /s/ Pardeep Kohli

		 	Pardeep Kohli, President
	
	Address:
	1700 International Parkway, Suite 200
	Richardson, TX 75081
	Facsimile: (469) 916-4393

 MAVENIR SYSTEMS, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year first set
forth above. 
  

			
	“Investor”
	
	Alloy Ventures 2005, L.P.
		
	By:	 	Alloy Ventures 2005, LLC,
		 	its General Partner
		
	By:	 	 /s/ Ammar Hanafi

	Print Name: Ammar Hanafi
	Title: Managing Member

  
 MAVENIR
SYSTEMS, INC. 
 AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 
 SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year first set
forth above. 
  

			
	“Investor”
	
	Austin Ventures VIII, L.P.
		
	By:	 	AV Partners VIII, L.P.,
		 	its General Partner
		
	By:	 	 /s/ Chris Pacitti

	Print Name: Chris Pacitti
	Title: General Partner

  
 MAVENIR
SYSTEMS, INC. 
 AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 
 SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year first set
forth above. 
  

			
	“Investor”
	
	North Bridge Venture Partners V-A, L.P.
		
	By:	 	North Bridge Venture Management V, L.P.
		 	Its General Partner
		
	By:	 	NBVM GP, LLC
		 	Its General Partner
		
	By:	 	 /s/ Jeffrey P. McCarthy

		 	Jeffrey P. McCarthy
		 	Manager
	
	North Bridge Venture Partners V-B, L.P.
		
	By:	 	North Bridge Venture Management V, L.P.
		 	Its General Partner
		
	By:	 	NBVM GP, LLC
		 	Its General Partner
		
	By:	 	 /s/ Jeffrey P. McCarthy

		 	Jeffrey P. McCarthy
		 	Manager
	
	North Bridge Venture Partners VI, L.P.
		
	By:	 	North Bridge Venture Management VI, L.P.
		 	Its General Partner
		
	By:	 	NBVM GP, LLC
		 	Its General Partner
		
	By:	 	 /s/ Jeffrey P. McCarthy

		 	Jeffrey P. McCarthy
		 	Manager

  
 MAVENIR
SYSTEMS, INC. 
 AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 
 SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year first set
forth above. 
  

			
	
	“Investor”
	
	August Capital V Special Opportunities, L.P.
		
	By:	 	August Capital Management V, L.L.C.
		 	Its general partner
		
	By:	 	 /s/ Jeffrey Bloom

	Name:	 	Jeffrey Bloom
	Title:	 	Attorney-in-Fact

  
 MAVENIR
SYSTEMS, INC. 
 AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 
 SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year first set
forth above. 
  

			
	“Investor”
	
	Cross Creek Capital, L.P.
		
	By:	 	Cross Creek Capital GP, L.P.,
		 	its Sole General Partner
		
	By:	 	Cross Creek Capital, LLC,
		 	its Sole General Partner
		
	By:	 	Wasatch Advisors, Inc.,
		 	its Sole Member
		
	By:	 	 
	Print Name: Daniel Thurber
	Title:	 	Vice President

  
 MAVENIR
SYSTEMS, INC. 
 AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 
 SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year first set
forth above. 
  

			
	“Investor”
	
	Cross Creek Capital Employees’ Fund, L.P.
		
	By:	 	Cross Creek Capital GP, L.P.,
		 	its Sole General Partner
		
	By:	 	Cross Creek Capital, LLC,
		 	its Sole General Partner
		
	By:	 	Wasatch Advisors, Inc.,
		 	its Sole Member
		
	By:	 	 
	Print Name: Daniel Thurber
	Title:	 	Vice President

  
 MAVENIR
SYSTEMS, INC. 
 AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 
 SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year first set
forth above. 
  

			
	 “Investor”

	
	 KAM Patel, LLC

		
	 By:
	 	 
	 Print Name:
	 	 
	 Title:
	 	 

  
 MAVENIR
SYSTEMS, INC. 
 AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 
 SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year first set
forth above. 
  

			
	“Investor”
	
	Starent Networks LLC
		
	By:	 	 
	Print Name:	 	 
	Title:	 	 
		
	Address:	 	c/o Cicso Systems, Inc.
		 	San Jose, CA 95134-1706
		 	Attention: General Counsel
	Facsimile:	 	(408) 525-4757
	Attention:	 	SVP, Corporate Development
	Facsimile:	 	(408) 526-7864
	
	with a copy to:
	Fenwick & West LLP
	801 California Street
	Mountain View, CA 94041
	Attention: Cynthia Clarfield Hess, Esq.
	Facsimile: (650) 938-5200

  
 MAVENIR
SYSTEMS, INC. 
 AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 
 SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year first set
forth above. 
  

			
	“Investor”
	
	Greenspring Crossover Ventures I, L.P.
		
	By:	 	Greenspring Crossover I GP, L.P.
		
	By:	 	Greenspring Crossover I GP, LLC
		
	By:	 	 
	Name:	 	 
	Title:	 	 

  
 MAVENIR
SYSTEMS, INC. 
 AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 
 SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year first set
forth above. 
  

	
	“Investor”
	
	  
 Satish Kohli

  
 MAVENIR
SYSTEMS, INC. 
 AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 
 SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year first set
forth above. 
  

	
	 “Investor”

	
	  
 Pardeep
Kohli

  
 MAVENIR
SYSTEMS, INC. 
 AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 
 SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year first set
forth above. 
  

	
	 “Investor”

	
	  
 KiHyun
Joo

  
 MAVENIR
SYSTEMS, INC. 
 AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 
 SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year first set
forth above. 
  

	
	 “Investor”

	
	  
 Alex
Garbuz

  
 MAVENIR
SYSTEMS, INC. 
 AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 
 SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year first set
forth above. 
  

			
	 “Investor”

	
	  

K.P. Wilska

		
	 Facsimile:
	 	 

  
 MAVENIR
SYSTEMS, INC. 
 AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 
 SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year first set
forth above. 
  

	
	“Investor”
	
	  
 Ashok Khuntia

  
 MAVENIR
SYSTEMS, INC. 
 AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 
 SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year first set
forth above. 
  

	
	“Investor”
	
	  
 Satyendra Arya

  
 MAVENIR
SYSTEMS, INC. 
 AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 
 SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year first set
forth above. 
  

			
	“Investor”
	
	Koteswar Krishna Revocable Trust,
	Koteswar Krishna and Vijaya Krishna co-trustees
		
	By:	 	 
	Print Name: Koteswar Krishna
	Title: Co-Trustee
		
	By:	 	 
	Print Name: Vijaya Krishna
	Title: Co-Trustee

  
 MAVENIR
SYSTEMS, INC. 
 AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 
 SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year first set
forth above. 
  

	
	“Investor”
	
	 
	S. Paul Handa

  
 MAVENIR
SYSTEMS, INC. 
 AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 
 SIGNATURE PAGE 

 SCHEDULE A 

SCHEDULE OF INVESTORS 

August Capital V Special Opportunities, L.P. 
 Alloy Ventures
2005, L.P. 
 Satyendra Arya 
 Austin Ventures VIII, L.P. 

Alex Garbuz 
 Greenspring Crossover Ventures I, L.P. 

S. Paul Handa 
 North Bridge Venture Partners V-A, L.P. 

North Bridge Venture Partners V-B, L.P. 
 North Bridge Venture
Partners VI, L.P. 
 KAM Patel LLC 
 Ashok Khuntia 

KiHyun Joo 
 Pardeep Kohli 

Satish Kohli 
 Starent Networks LLC 

K-P Wilska 
 Cross Creek Capital, L.P. 

Cross Creek Capital Employees’ Fund, L.P. 
 Koteswar Krishna
Revocable Trust 

  
 S-1 

 SCHEDULE B 

SCHEDULE OF COMMON HOLDERS 

Pulin Patel 
 Rashad Ali 

Achal Patel 
 Jake Han 

  
 S-2 

 EXHIBIT A 

ADOPTION AGREEMENT 

This Adoption Agreement (“Adoption Agreement”) is executed by the undersigned (the
“Transferee”) pursuant to the terms of that certain Amended and Restated Investors’ Rights Agreement dated as of July 15, 2014 (the “Agreement”) by and among Mavenir Systems, Inc. (the
“Company”) and certain of its Capital Stock. Capitalized terms used but not defined herein shall have the respective meanings ascribed to such terms in the Agreement. By the execution of this Adoption Agreement, the
Transferee agrees as follows: 
 1. Acknowledgement. Transferee acknowledges that Transferee is
acquiring certain shares of the Capital Stock of the Company, which shares are subject to the terms and conditions of the Agreement. 

2. Agreement. As partial consideration for such transfer, Transferee (i) agrees that the Capital Stock
acquired by Transferee shall be bound by and subject to the terms of the Agreement, to the same extent and with the same rights and obligations as the person(s) from which such Capital Stock is received and (ii) hereby agrees to become a party
to the Agreement with the same force and effect as if Transferee were originally a party thereto. 
 3.
Notice. Any notice required or permitted by the Agreement shall be given to Transferee at the address listed below Transferee’s signature below. 

4. Joinder. The spouse of the undersigned Transferee, if applicable, executes this Adoption to acknowledge its
fairness and that it is in such spouse’s best interests and to bind to the terms of the Agreement such spouse’s community interest, if any, in the Capital Stock. 

EXECUTED AND DATED this          day
of                    ,             . 

 

			
	TRANSFEREE:
	
	  

	Title:	 	  

	Address:	 	  

	Fax:	 	  

	
	Spouse: (if applicable):
	
	  

	Name:	 	  

 Acknowledged and accepted
on                    ,             . 

 

			
	MAVENIR SYSTEMS, INC.
		
	By:	 	  

	Name:	 	  

	Title:	 	  

  
 Exhibit B

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}]]